(S)-8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid

ID: ALA5315124

Chembl Id: CHEMBL5315124

Max Phase: Approved

First Approval: 1996

Molecular Formula: C36H42F2N6O9

Molecular Weight: 361.37

Molecule Type: Small molecule

Names and Identifiers

Synonyms: Cravit | L-ofloxacin | Levofloxacin | Levofloxacin (as hemihydrate) | Levofloxacin hydrate | Nofaxin | Ofloxacin, (s)- | Volequin | DR-3355 | RWJ-25213

Trade Names(8): Evoxil | Iquix | Levaquin | Levofloxacin | Oftaquix | Quinsair | Quixin | Tavanic

Canonical SMILES:  C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23.C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23.O

Standard InChI:  InChI=1S/2C18H20FN3O4.H2O/c2*1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21;/h2*7-8,10H,3-6,9H2,1-2H3,(H,24,25);1H2/t2*10-;/m00./s1

Standard InChI Key:  SUIQUYDRLGGZOL-RCWTXCDDSA-N

Molecule Features

Natural Product: No

Oral: Yes

Chemical Probe: No

Parenteral: Yes

Molecule Type: Small molecule

Topical: Yes

First In Class: No

Black Box: Yes

Chirality: Yes

Availability: Yes

Prodrug: No

Calculated Properties

Molecular Weight: 361.37

Molecular Weight (Monoisotopic): 361.1438

AlogP: 1.54

#Rotatable Bonds: 2

Polar Surface Area: 75.01

Molecular Species: ACID

HBA: 6

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 5.29

CX Basic pKa: 6.16

CX LogP: 0.51

CX LogD: -0.47

Aromatic Rings: 2

Heavy Atoms: 26

QED Weighted: 0.87

Np Likeness Score: -0.21

References

1. Inagaki H, Miyauchi S, Miyauchi RN, Kawato HC, Ohki H, Matsuhashi N, Kawakami K, Takahashi H, Takemura M..  (2003)  Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.,  46  (6): [PMID:12620077] [10.1021/jm020328y]

2. Frigola J, Vañó D, Torrens A, Gómez-Gomar A, Ortega E, García-Granda S..  (1995)  7-Azetidinylquinolones as antibacterial agents. 3. Synthesis, properties and structure-activity relationships of the stereoisomers containing a 7-(3-amino-2-methyl-1-azetidinyl) moiety.,  38  (7): [PMID:7707323] [10.1021/jm00007a017]

3. Ohta M, Koga H..  (1991)  Three-dimensional structure-activity relationships and receptor mapping of N1-substituents of quinolone antibacterials.,  34  (1): [PMID:1992111] [10.1021/jm00105a020]

4. Wentland MP, Perni RB, Dorff PH, Rake JB..  (1988)  Synthesis and bacterial DNA gyrase inhibitory properties of a spirocyclopropylquinolone derivative.,  31  (9): [PMID:2842501] [10.1021/jm00117a005]

5. Wentland MP, Lesher GY, Reuman M, Pilling GM, Saindane MT, Perni RB, Eissenstat MA, Weaver JD, Singh B, Rake J, Coughlin SA.  (1993)  Relationship of structure of bridged (2,6-dimethyl-4-pyridinyl)quinolones to mammalian topoisomerase II inhibition,  3  (8): [10.1016/S0960-894X(00)80048-7]

6. Sakurai N, Sano M, Hirayama F, Kuroda T, Uemori S, Moriguchi A, Yamamoto K, Ikeda Y, Kawakita T..  (1998)  Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents.,  8  (16): [PMID:9873510] [10.1016/s0960-894x(98)00390-4]

7. Mitscher LA, Sharma PN, Chu DT, Shen LL, Pernet AG..  (1987)  Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin).,  30  (12): [PMID:2824776] [10.1021/jm00395a017]

8. Gray JL, Almstead JI, Gallagher CP, Hu XE, Kim NK, Taylor CJ, Twinem TL, Wallace CD, Ledoussal B..  (2003)  Synthesis and biological testing of non-fluorinated analogues of levofloxacin.,  13  (14): [PMID:12824037] [10.1016/s0960-894x(03)00399-8]

9. Renau TE, Léger R, Filonova L, Flamme EM, Wang M, Yen R, Madsen D, Griffith D, Chamberland S, Dudley MN, Lee VJ, Lomovskaya O, Watkins WJ, Ohta T, Nakayama K, Ishida Y..  (2003)  Conformationally-restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa.,  13  (16): [PMID:12873508] [10.1016/s0960-894x(03)00556-0]

10. Keserü GM..  (2003)  Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.,  13  (16): [PMID:12873512] [10.1016/s0960-894x(03)00492-x]

11. Cianchetta G, Mannhold R, Cruciani G, Baroni M, Cecchetti V..  (2004)  Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach.,  47  (12): [PMID:15163198] [10.1021/jm030986y]

12. Clark RF, Wang S, Ma Z, Weitzberg M, Motter C, Tufano M, Wagner R, Gu YG, Dandliker PJ, Lerner CG, Chovan LE, Cai Y, Black-Schaefer CL, Lynch L, Kalvin D, Nilius AM, Pratt SD, Soni N, Zhang T, Zhang X, Beutel BA..  (2004)  Novel inhibitors of bacterial protein synthesis: structure-activity relationships for 1,8-naphthyridine derivatives incorporating position 3 and 4 variants.,  14  (12): [PMID:15149694] [10.1016/j.bmcl.2004.03.091]

13. Nakayama K, Ishida Y, Ohtsuka M, Kawato H, Yoshida K, Yokomizo Y, Ohta T, Hoshino K, Otani T, Kurosaka Y, Yoshida K, Ishida H, Lee VJ, Renau TE, Watkins WJ..  (2003)  MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 2: achieving activity in vivo through the use of alternative scaffolds.,  13  (23): [PMID:14623002] [10.1016/j.bmcl.2003.07.027]

14. Colmenarejo G, Alvarez-Pedraglio A, Lavandera JL..  (2001)  Cheminformatic models to predict binding affinities to human serum albumin.,  44  (25): [PMID:11728183] [10.1021/jm010960b]

15. Zloh M, Kaatz GW, Gibbons S..  (2004)  Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.,  14  (4): [PMID:15012986] [10.1016/j.bmcl.2003.12.015]

16. Inagaki H, Takahashi H, Takemura M..  (2004)  Synthesis and antibacterial activity of novel 6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-4-oxoquinoline-3-carboxylic acids bearing cyclopropane-fused 2-amino-8-azabicyclo[4.3.0]nonan-8-yl substituents at the C-7 position.,  14  (20): [PMID:15380226] [10.1016/j.bmcl.2004.07.064]

17. de Souza NJ, Gupte SV, Deshpande PK, Desai VN, Bhawsar SB, Yeole RD, Shukla MC, Strahilevitz J, Hooper DC, Bozdogan B, Appelbaum PC, Jacobs MR, Shetty N, Patel MV, Jha R, Khorakiwala HF..  (2005)  A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.,  48  (16): [PMID:16078842] [10.1021/jm050035f]

18. Tobita M, Nishikawa T, Nagashima R..  (2005)  A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.,  15  (11): [PMID:15911273] [10.1016/j.bmcl.2005.03.080]

19. Matthew Hansen T, Gu YG, Rehm TM, Dandliker PJ, Chovan LE, Bui MH, Nilius AM, Beutel BA..  (2005)  Synthesis and antibacterial activity of 5-methoxy- and 5-hydroxy-6-fluoro-1,8-naphthyridone-3-carboxylic acid derivatives.,  15  (11): [PMID:15911248] [10.1016/j.bmcl.2005.04.007]

20. Ellsworth EL, Tran TP, Showalter HD, Sanchez JP, Watson BM, Stier MA, Domagala JM, Gracheck SJ, Joannides ET, Shapiro MA, Dunham SA, Hanna DL, Huband MD, Gage JW, Bronstein JC, Liu JY, Nguyen DQ, Singh R..  (2006)  3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms.,  49  (22): [PMID:17064062] [10.1021/jm060505l]

21. Wang Q, Lucien E, Hashimoto A, Pais GC, Nelson DM, Song Y, Thanassi JA, Marlor CW, Thoma CL, Cheng J, Podos SD, Ou Y, Deshpande M, Pucci MJ, Buechter DD, Bradbury BJ, Wiles JA..  (2007)  Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.,  50  (2): [PMID:17228862] [10.1021/jm060844e]

22. Chen S, Cui S, McDermott PF, Zhao S, White DG, Paulsen I, Meng J..  (2007)  Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.,  51  (2): [PMID:17043131] [10.1128/aac.00600-06]

23. Pai H, Seo MR, Choi TY..  (2007)  Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.,  51  (1): [PMID:17074790] [10.1128/aac.00841-06]

24. Weigel LM, Donlan RM, Shin DH, Jensen B, Clark NC, McDougal LK, Zhu W, Musser KA, Thompson J, Kohlerschmidt D, Dumas N, Limberger RJ, Patel JB..  (2007)  High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm.,  51  (1): [PMID:17074796] [10.1128/aac.00576-06]

25. Foleno BD, Abbanat D, Goldschmidt RM, Flamm RK, Paget SD, Webb GC, Wira E, Macielag MJ, Bush K..  (2007)  In vitro antibacterial activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457.,  51  (1): [PMID:17101672] [10.1128/aac.01017-06]

26. Escudero JA, San Millan A, Catalan A, de la Campa AG, Rivero E, Lopez G, Dominguez L, Moreno MA, Gonzalez-Zorn B..  (2007)  First characterization of fluoroquinolone resistance in Streptococcus suis.,  51  (2): [PMID:17116660] [10.1128/aac.00972-06]

27. Szumowski JD, Cohen DE, Kanaya F, Mayer KH..  (2007)  Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic.,  51  (2): [PMID:17116664] [10.1128/aac.01244-06]

28. Kosowska-Shick K, Credito KL, Pankuch GA, DeWasse B, McGhee P, Appelbaum PC..  (2007)  Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.,  51  (2): [PMID:17116666] [10.1128/aac.01150-06]

29. Rozen DE, McGee L, Levin BR, Klugman KP..  (2007)  Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.,  51  (2): [PMID:17116668] [10.1128/aac.01161-06]

30. Kim IS, Ki CS, Kim S, Oh WS, Peck KR, Song JH, Lee K, Lee NY..  (2007)  Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea.,  51  (2): [PMID:17116681] [10.1128/aac.00960-06]

31. Chan YY, Ong YM, Chua KL..  (2007)  Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.,  51  (2): [PMID:17145801] [10.1128/aac.01033-06]

32. Vidaillac C, Guillon J, Arpin C, Forfar-Bares I, Ba BB, Grellet J, Moreau S, Caignard DH, Jarry C, Quentin C..  (2007)  Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.,  51  (3): [PMID:17101679] [10.1128/aac.01306-05]

33. Izdebski R, Sadowy E, Fiett J, Grzesiowski P, Gniadkowski M, Hryniewicz W..  (2007)  Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland.,  51  (4): [PMID:17210772] [10.1128/aac.01384-06]

34. Hong SG, Moland ES, Wickman PA, Black JA, Hossain A, Hanson ND, Thomson KS..  (2007)  In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.,  51  (4): [PMID:17220419] [10.1128/aac.00959-06]

35. Castanheira M, Pereira AS, Nicoletti AG, Pignatari AC, Barth AL, Gales AC..  (2007)  First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America.,  51  (4): [PMID:17220425] [10.1128/aac.00780-06]

36. Pucci MJ, Cheng J, Podos SD, Thoma CL, Thanassi JA, Buechter DD, Mushtaq G, Vigliotti GA, Bradbury BJ, Deshpande M..  (2007)  In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.,  51  (4): [PMID:17242152] [10.1128/aac.01315-06]

37. Huband MD, Cohen MA, Zurack M, Hanna DL, Skerlos LA, Sulavik MC, Gibson GW, Gage JW, Ellsworth E, Stier MA, Gracheck SJ..  (2007)  In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups.,  51  (4): [PMID:17261623] [10.1128/aac.01321-06]

38. Credito K, Lin G, Appelbaum PC..  (2007)  Antistaphylococcal activity of DX-619 alone and in combination with vancomycin, teicoplanin, and linezolid assessed by time-kill synergy testing.,  51  (4): [PMID:17261625] [10.1128/aac.01517-06]

39. Pérez-Vázquez M, Román F, García-Cobos S, Campos J..  (2007)  Fluoroquinolone resistance in Haemophilus influenzae is associated with hypermutability.,  51  (4): [PMID:17283196] [10.1128/aac.01437-06]

40. LaPlante KL, Rybak MJ, Tsuji B, Lodise TP, Kaatz GW..  (2007)  Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.,  51  (4): [PMID:17296740] [10.1128/aac.00646-06]

41. Murphy ST, Case HL, Ellsworth E, Hagen S, Huband M, Joannides T, Limberakis C, Marotti KR, Ottolini AM, Rauckhorst M, Starr J, Stier M, Taylor C, Zhu T, Blaser A, Denny WA, Lu GL, Smaill JB, Rivault F..  (2007)  The synthesis and biological evaluation of novel series of nitrile-containing fluoroquinolones as antibacterial agents.,  17  (8): [PMID:17303420] [10.1016/j.bmcl.2007.01.090]

42. Ikee Y, Hashimoto K, Nakashima M, Hayashi K, Sano S, Shiro M, Nagao Y..  (2007)  Synthesis and antibacterial activities of new quinolone derivatives utilizing 1-azabicyclo[1.1.0]butane.,  17  (4): [PMID:17157008] [10.1016/j.bmcl.2006.11.048]

43. Foroumadi A, Emami S, Mansouri S, Javidnia A, Saeid-Adeli N, Shirazi FH, Shafiee A..  (2007)  Synthesis and antibacterial activity of levofloxacin derivatives with certain bulky residues on piperazine ring.,  42  (7): [PMID:17316916] [10.1016/j.ejmech.2006.12.034]

44. Lv J, Qian Y, Liu T, Wang Y..  (2007)  Synthesis and evaluation of amphiphilic cationic quinine-derived for antibacterial activity against methicillin-resistant Staphylococcus aureus.,  17  (15): [PMID:17570664] [10.1016/j.bmcl.2007.05.065]

45. Zhang Z, Yu A, Zhou W..  (2007)  Synthesis and structure-activity relationship of 7-(substituted)-aminomethyl-4-quinolone-3-carboxylic acid derivatives.,  15  (23): [PMID:17826097] [10.1016/j.bmc.2007.08.031]

46. Moda TL, Montanari CA, Andricopulo AD..  (2007)  Hologram QSAR model for the prediction of human oral bioavailability.,  15  (24): [PMID:17870541] [10.1016/j.bmc.2007.08.060]

47. Moda TL, Montanari CA, Andricopulo AD..  (2007)  Hologram QSAR model for the prediction of human oral bioavailability.,  15  (24): [PMID:17870541] [10.1016/j.bmc.2007.08.060]

48. Hirokawa Y, Kinoshita H, Tanaka T, Nakata K, Kitadai N, Fujimoto K, Kashimoto S, Kojima T, Kato S..  (2008)  Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.,  51  (7): [PMID:18330977] [10.1021/jm8000136]

49. Stucki A, Cottagnoud M, Winkelmann V, Schaffner T, Cottagnoud P..  (2007)  Daptomycin produces an enhanced bactericidal activity compared to ceftriaxone, measured by [3H]choline release in the cerebrospinal fluid, in experimental meningitis due to a penicillin-resistant pneumococcal strain without lysing its cell wall.,  51  (6): [PMID:17371817] [10.1128/aac.01000-06]

50. Yamazaki T, Sasaki T, Takahata M..  (2007)  Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae.,  51  (6): [PMID:17387152] [10.1128/aac.01561-06]

51. Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, Citton R, D'Inzeo T, Fadda G, Cauda R, Spanu T..  (2007)  Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.,  51  (6): [PMID:17387156] [10.1128/aac.01509-06]

52. Endimiani A, Luzzaro F, Migliavacca R, Mantengoli E, Hujer AM, Hujer KM, Pagani L, Bonomo RA, Rossolini GM, Toniolo A..  (2007)  Spread in an Italian hospital of a clonal Acinetobacter baumannii strain producing the TEM-92 extended-spectrum beta-lactamase.,  51  (6): [PMID:17404005] [10.1128/aac.01139-06]

53. Rodríguez-Martínez JM, Velasco C, García I, Cano ME, Martínez-Martínez L, Pascual A..  (2007)  Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.,  51  (6): [PMID:17404007] [10.1128/aac.01444-06]

54. Gentry DR, Rittenhouse SF, McCloskey L, Holmes DJ..  (2007)  Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin.,  51  (6): [PMID:17404009] [10.1128/aac.01066-06]

55. Matrat S, Petrella S, Cambau E, Sougakoff W, Jarlier V, Aubry A..  (2007)  Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.,  51  (5): [PMID:17325221] [10.1128/aac.01282-06]

56. Lodise TP, Kwa A, Cosler L, Gupta R, Smith RP..  (2007)  Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.,  51  (11): [PMID:17709460] [10.1128/aac.00006-07]

57. Ip M, Chau SS, Chi F, Tang J, Chan PK..  (2007)  Fluoroquinolone resistance in atypical pneumococci and oral streptococci: evidence of horizontal gene transfer of fluoroquinolone resistance determinants from Streptococcus pneumoniae.,  51  (8): [PMID:17548487] [10.1128/aac.00258-07]

58. Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN..  (2007)  In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.,  51  (8): [PMID:17517836] [10.1128/aac.01623-06]

59. Louie A, Deziel MR, Liu W, Drusano GL..  (2007)  Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy.,  51  (8): [PMID:17517837] [10.1128/aac.00073-07]

60. Adams DA, Riggs MM, Donskey CJ..  (2007)  Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.,  51  (8): [PMID:17562807] [10.1128/aac.01582-06]

61. Asahina Y, Takei M, Kimura T, Fukuda Y..  (2008)  Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent.,  51  (11): [PMID:18457383] [10.1021/jm701428b]

62. Jia L, Sun H..  (2008)  Support vector machines classification of hERG liabilities based on atom types.,  16  (11): [PMID:18448342] [10.1016/j.bmc.2008.04.028]

63. Gould CV, Sniegowski PD, Shchepetov M, Metlay JP, Weiser JN..  (2007)  Identifying mutator phenotypes among fluoroquinolone-resistant strains of Streptococcus pneumoniae using fluctuation analysis.,  51  (9): [PMID:17664329] [10.1128/aac.00336-07]

64. Yamane K, Wachino J, Suzuki S, Kimura K, Shibata N, Kato H, Shibayama K, Konda T, Arakawa Y..  (2007)  New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.,  51  (9): [PMID:17548499] [10.1128/aac.00339-07]

65. Arsène S, Leclercq R..  (2007)  Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.,  51  (9): [PMID:17620379] [10.1128/aac.00274-07]

66. Calatayud L, Ardanuy C, Cercenado E, Fenoll A, Bouza E, Pallares R, Martín R, Liñares J..  (2007)  Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain.,  51  (9): [PMID:17606677] [10.1128/aac.00157-07]

67. Billal DS, Hotomi M, Yamanaka N..  (2007)  Can the Etest correctly determine the MICs of beta-lactam and cephalosporin antibiotics for beta-lactamase-negative ampicillin-resistant Haemophilus influenzae?,  51  (9): [PMID:17606681] [10.1128/aac.00190-07]

68. Kroeger LA, Hovde LB, Mitropoulos IF, Schafer J, Rotschafer JC..  (2007)  Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.,  51  (9): [PMID:17576842] [10.1128/aac.01433-06]

69. Jansen WT, Verel A, Verhoef J, Milatovic D..  (2007)  In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.,  51  (9): [PMID:17606689] [10.1128/aac.00100-07]

70. Kohno Y, Ohno H, Miyazaki Y, Higashiyama Y, Yanagihara K, Hirakata Y, Fukushima K, Kohno S..  (2007)  In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.,  51  (11): [PMID:17709469] [10.1128/aac.00410-07]

71. Bogdanovich T, Clark C, Kosowska-Shick K, Dewasse B, McGhee P, Appelbaum PC..  (2007)  Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.,  51  (11): [PMID:17875997] [10.1128/aac.00550-07]

72. Xu X, Wu S, Ye X, Liu Y, Shi W, Zhang Y, Wang M..  (2007)  Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.,  51  (11): [PMID:17724159] [10.1128/aac.00616-07]

73. Wang H, Guo P, Sun H, Wang H, Yang Q, Chen M, Xu Y, Zhu Y..  (2007)  Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.,  51  (11): [PMID:17846127] [10.1128/aac.01259-06]

74. Liu J, Cao R, Wu Q, Ma C, Wang Z, Peng W, Song H..  (2009)  Synthesis and antibacterial evaluation of novel 4-alkyl substituted phenyl beta-aldehyde ketone derivatives.,  44  (4): [PMID:18450331] [10.1016/j.ejmech.2008.03.010]

75. Hotomi M, Fujihara K, Billal DS, Suzuki K, Nishimura T, Baba S, Yamanaka N..  (2007)  Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan.,  51  (11): [PMID:17698631] [10.1128/aac.00422-07]

76. Henrichfreise B, Wiegand I, Luhmer-Becker I, Wiedemann B..  (2007)  Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.,  51  (10): [PMID:17682103] [10.1128/aac.00160-07]

77. Shin JH, Jung HJ, Kim HR, Jeong J, Jeong SH, Kim S, Lee EY, Lee JN, Chang CL..  (2007)  Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea.,  51  (7): [PMID:17502407] [10.1128/aac.00107-07]

78. Trampuz A, Murphy CK, Rothstein DM, Widmer AF, Landmann R, Zimmerli W..  (2007)  Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection.,  51  (7): [PMID:17502404] [10.1128/aac.00120-07]

79. Périchon B, Courvalin P, Galimand M..  (2007)  Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.,  51  (7): [PMID:17470656] [10.1128/aac.00143-07]

80. Yum JH, Kim CK, Yong D, Lee K, Chong Y, Kim CM, Kim JM, Ro S, Cho JM..  (2007)  In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea.,  51  (7): [PMID:17420210] [10.1128/aac.01562-06]

81. Griffith ME, Moon JE, Johnson EN, Clark KP, Hawley JS, Hospenthal DR, Murray CK..  (2007)  Efficacy of fluoroquinolones against Leptospira interrogans in a hamster model.,  51  (7): [PMID:17470646] [10.1128/aac.00240-07]

82. Mendes RE, Castanheira M, Toleman MA, Sader HS, Jones RN, Walsh TR..  (2007)  Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.,  51  (7): [PMID:17470660] [10.1128/aac.00838-06]

83. Critchley IA, Brown SD, Traczewski MM, Tillotson GS, Janjic N..  (2007)  National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.,  51  (12): [PMID:17908940] [10.1128/aac.00971-07]

84. Clark CL, Kosowska-Shick K, Ednie LM, Appelbaum PC..  (2007)  Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.,  51  (11): [PMID:17876003] [10.1128/aac.00827-07]

85. Morio F, Jean-Pierre H, Dubreuil L, Jumas-Bilak E, Calvet L, Mercier G, Devine R, Marchandin H..  (2007)  Antimicrobial susceptibilities and clinical sources of Dialister species.,  51  (12): [PMID:17923492] [10.1128/aac.00538-07]

86. Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R, Matsubara K, Nakayama E, Sunakawa K, Ubukata K, Acute Respiratory Diseases Study Group..  (2008)  Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia.,  52  (1): [PMID:17954691] [10.1128/aac.00779-07]

87. Quiroga MP, Andres P, Petroni A, Soler Bistué AJ, Guerriero L, Vargas LJ, Zorreguieta A, Tokumoto M, Quiroga C, Tolmasky ME, Galas M, Centrón D..  (2007)  Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.,  51  (12): [PMID:17938184] [10.1128/aac.00726-07]

88. Clark C, Smith K, Ednie L, Bogdanovich T, Dewasse B, McGhee P, Appelbaum PC..  (2008)  In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.,  52  (1): [PMID:17938189] [10.1128/aac.01229-07]

89. Zhu W, Clark NC, McDougal LK, Hageman J, McDonald LC, Patel JB..  (2008)  Vancomycin-resistant Staphylococcus aureus isolates associated with Inc18-like vanA plasmids in Michigan.,  52  (2): [PMID:18056272] [10.1128/aac.00908-07]

90. Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A..  (2009)  Physicochemical determinants of human renal clearance.,  52  (15): [PMID:19445515] [10.1021/jm900403j]

91. Damier-Piolle L, Magnet S, Brémont S, Lambert T, Courvalin P..  (2008)  AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.,  52  (2): [PMID:18086852] [10.1128/aac.00732-07]

92. Homma T, Hori T, Sugimori G, Yamano Y..  (2007)  Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.,  51  (11): [PMID:17664314] [10.1128/aac.01372-06]

93. Morgan-Linnell SK, Zechiedrich L..  (2007)  Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli.,  51  (11): [PMID:17682104] [10.1128/aac.00647-07]

94. Zong Z, Partridge SR, Iredell JR..  (2008)  RmtC 16S rRNA methyltransferase in Australia.,  52  (2): [PMID:18025117] [10.1128/aac.01399-07]

95. Louie A, Brown DL, Liu W, Kulawy RW, Deziel MR, Drusano GL..  (2007)  In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.,  51  (11): [PMID:17846144] [10.1128/aac.00391-07]

96. Yan Q, Cao R, Yi W, Chen Z, Wen H, Ma L, Song H..  (2009)  Inhibitory effects of 5-benzylidene barbiturate derivatives on mushroom tyrosinase and their antibacterial activities.,  44  (10): [PMID:19552984] [10.1016/j.ejmech.2009.05.023]

97. Azéma J, Guidetti B, Dewelle J, Le Calve B, Mijatovic T, Korolyov A, Vaysse J, Malet-Martino M, Martino R, Kiss R..  (2009)  7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.,  17  (15): [PMID:19595598] [10.1016/j.bmc.2009.06.053]

98. Chai Y, Wan ZL, Wang B, Guo HY, Liu ML..  (2009)  Synthesis and in vitro antibacterial activity of 7-(4-alkoxyimino-3-amino-3-methylpiperidin-1-yl)fluoroquinolone derivatives.,  44  (10): [PMID:19481308] [10.1016/j.ejmech.2009.04.041]

99. Güzeldemirci NU, Küçükbasmaci O..  (2010)  Synthesis and antimicrobial activity evaluation of new 1,2,4-triazoles and 1,3,4-thiadiazoles bearing imidazo[2,1-b]thiazole moiety.,  45  (1): [PMID:19939519] [10.1016/j.ejmech.2009.09.024]

100. Miguet L, Zervosen A, Gerards T, Pasha FA, Luxen A, Distèche-Nguyen M, Thomas A..  (2009)  Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.,  52  (19): [PMID:19746934] [10.1021/jm900625q]

101. Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD..  (2010)  Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.,  53  (3): [PMID:20070106] [10.1021/jm901371v]

102. Patel MN, Chhasatia MR, Gandhi DS..  (2009)  Interaction of drug based binuclear mixed-ligand complexes with DNA.,  17  (15): [PMID:19581101] [10.1016/j.bmc.2009.06.023]

103. Miyauchi R, Kawakami K, Ito M, Matsuhashi N, Ohki H, Inagaki H, Takahashi H, Takemura M..  (2009)  Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.,  17  (19): [PMID:19736016] [10.1016/j.bmc.2009.08.026]

104. Sui X, Sun J, Li H, Wang Y, Liu J, Liu X, Zhang W, Chen L, He Z..  (2009)  Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.,  44  (11): [PMID:19586686] [10.1016/j.ejmech.2009.06.004]

105. Brillault J, De Castro WV, Couet W..  (2010)  Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.,  54  (1): [PMID:19822706] [10.1128/aac.00733-09]

106. Bae S, Lee J, Lee J, Kim E, Lee S, Yu J, Kang Y..  (2010)  Antimicrobial resistance in Haemophilus influenzae respiratory tract isolates in Korea: results of a nationwide acute respiratory infections surveillance.,  54  (1): [PMID:19884366] [10.1128/aac.00966-09]

107. Bulik CC, Christensen H, Nicolau DP..  (2010)  In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.,  54  (1): [PMID:19917762] [10.1128/aac.00912-09]

108. Sánchez MB, Martínez JL..  (2010)  SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia.,  54  (1): [PMID:19841154] [10.1128/aac.00496-09]

109. Kim HB, Wang M, Ahmed S, Park CH, LaRocque RC, Faruque AS, Salam MA, Khan WA, Qadri F, Calderwood SB, Jacoby GA, Hooper DC..  (2010)  Transferable quinolone resistance in Vibrio cholerae.,  54  (2): [PMID:19949057] [10.1128/aac.01045-09]

110. Padilla E, Llobet E, Doménech-Sánchez A, Martínez-Martínez L, Bengoechea JA, Albertí S..  (2010)  Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence.,  54  (1): [PMID:19858254] [10.1128/aac.00715-09]

111. King P, Lomovskaya O, Griffith DC, Burns JL, Dudley MN..  (2010)  In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.,  54  (1): [PMID:19805554] [10.1128/aac.00248-09]

112. Montes M, Tamayo E, Orden B, Larruskain J, Perez-Trallero E..  (2010)  Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.,  54  (1): [PMID:19805559] [10.1128/aac.00780-09]

113. Credito K, Kosowska-Shick K, McGhee P, Pankuch GA, Appelbaum PC..  (2010)  Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.,  54  (2): [PMID:20008781] [10.1128/aac.01353-09]

114. Al-Trawneh SA, Zahra JA, Kamal MR, El-Abadelah MM, Zani F, Incerti M, Cavazzoni A, Alfieri RR, Petronini PG, Vicini P..  (2010)  Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents.,  18  (16): [PMID:20667744] [10.1016/j.bmc.2010.06.098]

115. Chai Y, Liu M, Wang B, You X, Feng L, Zhang Y, Cao J, Guo H..  (2010)  Synthesis and in vitro antibacterial activity of novel fluoroquinolone derivatives containing substituted piperidines.,  20  (17): [PMID:20667731] [10.1016/j.bmcl.2010.07.006]

116. Pallecchi L, Riccobono E, Sennati S, Mantella A, Bartalesi F, Trigoso C, Gotuzzo E, Bartoloni A, Rossolini GM..  (2010)  Characterization of small ColE-like plasmids mediating widespread dissemination of the qnrB19 gene in commensal enterobacteria.,  54  (2): [PMID:20008783] [10.1128/aac.01160-09]

117. McGhee P, Clark C, Kosowska-Shick KM, Nagai K, Dewasse B, Beachel L, Appelbaum PC..  (2010)  In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.,  54  (1): [PMID:19884376] [10.1128/aac.01123-09]

118. Hood MI, Jacobs AC, Sayood K, Dunman PM, Skaar EP..  (2010)  Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.,  54  (3): [PMID:20028819] [10.1128/aac.00963-09]

119. Aytemir MD, Ozçelik B..  (2010)  A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities.,  45  (9): [PMID:20591538] [10.1016/j.ejmech.2010.05.069]

120. Lauderdale TL, Shiau YR, Lai JF, Chen HC, King CH..  (2010)  Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.,  54  (3): [PMID:20065058] [10.1128/aac.01197-09]

121. Robledo IE, Aquino EE, Santé MI, Santana JL, Otero DM, León CF, Vázquez GJ..  (2010)  Detection of KPC in Acinetobacter spp. in Puerto Rico.,  54  (3): [PMID:20038618] [10.1128/aac.00899-09]

122. Gozalbes R, Pineda-Lucena A..  (2010)  QSAR-based solubility model for drug-like compounds.,  18  (19): [PMID:20810286] [10.1016/j.bmc.2010.08.003]

123. Lehtopolku M, Nakari UM, Kotilainen P, Huovinen P, Siitonen A, Hakanen AJ..  (2010)  Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.,  54  (3): [PMID:20038624] [10.1128/aac.00898-09]

124. Pinho MD, Melo-Cristino J, Ramirez M, Portuguese Group for the Study of Streptococcal Infections..  (2010)  Fluoroquinolone resistance in Streptococcus dysgalactiae subsp. equisimilis and evidence for a shared global gene pool with Streptococcus pyogenes.,  54  (5): [PMID:20145082] [10.1128/aac.01377-09]

125. Wu HM, Janapatla RP, Ho YR, Hung KH, Wu CW, Yan JJ, Wu JJ..  (2008)  Emergence of fluoroquinolone resistance in group B streptococcal isolates in Taiwan.,  52  (5): [PMID:18299411] [10.1128/aac.00035-08]

126. Disratthakit A, Doi N..  (2010)  In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.,  54  (6): [PMID:20368403] [10.1128/aac.01545-09]

127. Balsalobre L, de la Campa AG..  (2008)  Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes.,  52  (3): [PMID:18160515] [10.1128/aac.00731-07]

128. de la Pedrosa EG, Morosini MI, van der Linden M, Ruiz-Garbajosa P, Galán JC, Baquero F, Reinert RR, Cantón R..  (2008)  Polyclonal population structure of Streptococcus pneumoniae isolates in Spain carrying mef and mef plus erm(B).,  52  (6): [PMID:18362188] [10.1128/aac.01487-07]

129. Stone GG, Girard D, Finegan S, Duignan J, Schafer J, Maloney M, Zaniewski RP, Brickner SJ, Wade SK, Le PT, Huband MD..  (2008)  In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.,  52  (7): [PMID:18426902] [10.1128/aac.01326-07]

130. Yamane K, Wachino J, Suzuki S, Arakawa Y..  (2008)  Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan.,  52  (4): [PMID:18285488] [10.1128/aac.01137-07]

131. Urich SK, Petersen JM..  (2008)  In vitro susceptibility of isolates of Francisella tularensis types A and B from North America.,  52  (6): [PMID:18411318] [10.1128/aac.01584-07]

132. Lawrence L, Danese P, DeVito J, Franceschi F, Sutcliffe J..  (2008)  In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.,  52  (5): [PMID:18316525] [10.1128/aac.01383-07]

133. Blango MG, Mulvey MA..  (2010)  Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.,  54  (5): [PMID:20231390] [10.1128/aac.00014-10]

134. Salas C, Calvo J, Martínez-Martínez L..  (2008)  Activity of Tigecycline against Coryneform Bacteria of Clinical Interest and Listeria monocytogenes.,  52  (4): [PMID:18227183] [10.1128/aac.01129-07]

135. Smith K, Ednie LM, Appelbaum PC, Hawser S, Lociuro S..  (2008)  Antistreptococcal activity of AR-709 compared to that of other agents.,  52  (6): [PMID:18362189] [10.1128/aac.01620-07]

136. Hsieh YC, Chang KY, Huang YC, Lin HC, Ho YH, Huang LM, Hsueh PR..  (2008)  Clonal spread of highly beta-lactam-resistant Streptococcus pneumoniae isolates in Taiwan.,  52  (6): [PMID:18413298] [10.1128/aac.00046-08]

137. Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF..  (2008)  Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.,  52  (7): [PMID:18443115] [10.1128/aac.01641-07]

138. Ressner RA, Moore MR, Jorgensen JH..  (2008)  Activity of the Diaminopyrimidine AR-709 against recently collected multidrug-resistant isolates of invasive Streptococcus pneumoniae from North America.,  52  (3): [PMID:18180346] [10.1128/aac.01387-07]

139. Lin YC, Hsia KC, Chen YC, Sheng WH, Chang SC, Liao MH, Li SY..  (2010)  Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.,  54  (5): [PMID:20194701] [10.1128/aac.01398-09]

140. Kaniga K, Flamm R, Tong SY, Lee M, Friedland I, Redman R..  (2010)  Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.,  54  (5): [PMID:20211892] [10.1128/aac.01450-09]

141. Mendes RE, Moet GJ, Janechek MJ, Jones RN..  (2010)  In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.,  54  (6): [PMID:20385851] [10.1128/aac.00301-10]

142. Endimiani A, Carias LL, Hujer AM, Bethel CR, Hujer KM, Perez F, Hutton RA, Fox WR, Hall GS, Jacobs MR, Paterson DL, Rice LB, Jenkins SG, Tenover FC, Bonomo RA..  (2008)  Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.,  52  (7): [PMID:18426899] [10.1128/aac.00158-08]

143. Brown SD, Traczewski MM..  (2010)  Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges.,  54  (5): [PMID:20231392] [10.1128/aac.01569-09]

144. Biedenbach DJ, Ross JE, Putnam SD, Jones RN..  (2010)  In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp.,  54  (5): [PMID:20308391] [10.1128/aac.00090-10]

145. Crandon JL, Bulik CC, Kuti JL, Nicolau DP..  (2010)  Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa.,  54  (3): [PMID:20038614] [10.1128/aac.01183-09]

146. Sader HS, Fritsche TR, Jones RN..  (2008)  Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.,  52  (3): [PMID:18180353] [10.1128/aac.01351-07]

147. Morrow BJ, He W, Amsler KM, Foleno BD, Macielag MJ, Lynch AS, Bush K..  (2010)  In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.,  54  (5): [PMID:20176911] [10.1128/aac.01374-09]

148. Zhanel GG, DeCorby M, Laing N, Weshnoweski B, Vashisht R, Tailor F, Nichol KA, Wierzbowski A, Baudry PJ, Karlowsky JA, Lagacé-Wiens P, Walkty A, McCracken M, Mulvey MR, Johnson J, Canadian Antimicrobial Resistance Alliance (CARA), Hoban DJ..  (2008)  Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.,  52  (4): [PMID:18285482] [10.1128/aac.01538-07]

149. Baudry PJ, Nichol K, DeCorby M, Mataseje L, Mulvey MR, Hoban DJ, Zhanel GG..  (2008)  Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.,  52  (5): [PMID:18299417] [10.1128/aac.01176-07]

150. Krause KM, Renelli M, Difuntorum S, Wu TX, Debabov DV, Benton BM..  (2008)  In vitro activity of telavancin against resistant gram-positive bacteria.,  52  (7): [PMID:18443122] [10.1128/aac.01398-07]

151. Laohavaleeson S, Tessier PR, Nicolau DP..  (2008)  Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains.,  52  (7): [PMID:18411322] [10.1128/aac.01422-07]

152. Critchley IA, Jacobs MR, Brown SD, Traczewski MM, Tillotson GS, Janjic N..  (2008)  Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.,  52  (7): [PMID:18443117] [10.1128/aac.00310-08]

153. Peloquin CA, Hadad DJ, Molino LP, Palaci M, Boom WH, Dietze R, Johnson JL..  (2008)  Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.,  52  (3): [PMID:18070980] [10.1128/aac.01036-07]

154. Ressner RA, Griffith ME, Beckius ML, Pimentel G, Miller RS, Mende K, Fraser SL, Galloway RL, Hospenthal DR, Murray CK..  (2008)  Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.,  52  (8): [PMID:18411316] [10.1128/aac.00044-08]

155. Hoshi S, Kikuchi K, Sasaki T, Sotozono C, Kinoshita S, Hiramatsu K..  (2008)  Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcus aureus strains.,  52  (8): [PMID:18490505] [10.1128/aac.01466-07]

156. Robertson GT, Bonventre EJ, Doyle TB, Du Q, Duncan L, Morris TW, Roche ED, Yan D, Lynch AS..  (2008)  In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.,  52  (7): [PMID:18443108] [10.1128/aac.01649-07]

157. Chmelnitsky I, Navon-Venezia S, Strahilevitz J, Carmeli Y..  (2008)  Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.,  52  (8): [PMID:18519713] [10.1128/aac.01341-07]

158. Moland ES, Craft DW, Hong SG, Kim SY, Hachmeister L, Sayed SD, Thomson KS..  (2008)  In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.,  52  (8): [PMID:18519722] [10.1128/aac.01581-07]

159. Koga T, Masuda N, Kakuta M, Namba E, Sugihara C, Fukuoka T..  (2008)  Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.,  52  (8): [PMID:18519723] [10.1128/aac.00413-08]

160. Yang H, Chen H, Yang Q, Chen M, Wang H..  (2008)  High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.,  52  (12): [PMID:18809939] [10.1128/aac.00830-08]

161. Shimizu K, Kikuchi K, Sasaki T, Takahashi N, Ohtsuka M, Ono Y, Hiramatsu K..  (2008)  Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.,  52  (10): [PMID:18644963] [10.1128/aac.00026-08]

162. Pomba C, da Fonseca JD, Baptista BC, Correia JD, Martínez-Martínez L..  (2009)  Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.,  53  (1): [PMID:19001117] [10.1128/aac.00896-08]

163. Cattoir V, Poirel L, Nordmann P..  (2008)  Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.,  52  (10): [PMID:18644958] [10.1128/aac.00638-08]

164. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Cantón R, Baquero F..  (2010)  Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrobial Resistance Trends (SMART).,  54  (7): [PMID:20421398] [10.1128/aac.00265-10]

165. Pérez-Trallero E, Martín-Herrero JE, Mazón A, García-Delafuente C, Robles P, Iriarte V, Dal-Ré R, García-de-Lomas J, Spanish Surveillance Group for Respiratory Pathogens..  (2010)  Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).,  54  (7): [PMID:20439616] [10.1128/aac.01548-09]

166. Fenoll A, Aguilar L, Robledo O, Giménez MJ, Granizo JJ, Biek D, Tarragó D..  (2008)  In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.,  52  (11): [PMID:18725443] [10.1128/aac.00712-08]

167. Zapor MJ, Barber M, Summers A, Miller GH, Feeney LA, Eberly LE, Wortmann G..  (2010)  In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center.,  54  (7): [PMID:20404121] [10.1128/aac.01173-09]

168. Waites KB, Crabb DM, Duffy LB..  (2008)  Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas.,  52  (10): [PMID:18663020] [10.1128/aac.00849-08]

169. Rossolini GM, Luzzaro F, Migliavacca R, Mugnaioli C, Pini B, De Luca F, Perilli M, Pollini S, Spalla M, Amicosante G, Toniolo A, Pagani L..  (2008)  First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.,  52  (11): [PMID:18809945] [10.1128/aac.00707-08]

170. Leavitt A, Carmeli Y, Chmelnitsky I, Goren MG, Ofek I, Navon-Venezia S..  (2010)  Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.,  54  (7): [PMID:20350950] [10.1128/aac.01818-09]

171. Pucci MJ, Ackerman M, Thanassi JA, Shoen CM, Cynamon MH..  (2010)  In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.,  54  (8): [PMID:20516287] [10.1128/aac.00287-10]

172. Amsler KM, Davies TA, Shang W, Jacobs MR, Bush K..  (2008)  In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.,  52  (9): [PMID:18591277] [10.1128/aac.00336-08]

173. Gentry DR, McCloskey L, Gwynn MN, Rittenhouse SF, Scangarella N, Shawar R, Holmes DJ..  (2008)  Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus.,  52  (12): [PMID:18838584] [10.1128/aac.00915-08]

174. Bennett JW, Herrera ML, Lewis JS, Wickes BW, Jorgensen JH..  (2009)  KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient.,  53  (1): [PMID:18852270] [10.1128/aac.00931-08]

175. Fernández-Roblas R, Martín-de-Hijas NZ, Fernández-Martínez AI, García-Almeida D, Gadea I, Esteban J..  (2008)  In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.,  52  (11): [PMID:18725441] [10.1128/aac.00695-08]

176. Bae IK, Park I, Lee JJ, Sun HI, Park KS, Lee JE, Ahn JH, Lee SH, Woo GJ..  (2010)  Novel variants of the qnrB gene, qnrB22 and qnrB23, in Citrobacter werkmanii and Citrobacter freundii.,  54  (7): [PMID:20421404] [10.1128/aac.01339-09]

177. McCalla C, Smyth DS, Robinson DA, Steenbergen J, Luperchio SA, Moise PA, Fowler VG, Sakoulas G..  (2008)  Microbiological and genotypic analysis of methicillin-resistant Staphylococcus aureus bacteremia.,  52  (9): [PMID:18606839] [10.1128/aac.00357-08]

178. Nagano N, Nagano Y, Kimura K, Tamai K, Yanagisawa H, Arakawa Y..  (2008)  Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.,  52  (12): [PMID:18809936] [10.1128/aac.00596-08]

179. Pires R, Ardanuy C, Rolo D, Morais A, Brito-Avô A, Gonçalo-Marques J, Liñares J, Santos-Sanches I..  (2010)  Emergence of ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates from healthy children and pediatric patients in Portugal.,  54  (6): [PMID:20350943] [10.1128/aac.01536-09]

180. Guo Q, Feng LS, Liu ML, Zhang YB, Chai Y, Lv K, Guo HY, Han LY..  (2010)  Synthesis and in vitro antibacterial activity of fluoroquinolone derivatives containing 3-(N'-alkoxycarbamimidoyl)-4-(alkoxyimino) pyrrolidines.,  45  (11): [PMID:20833454] [10.1016/j.ejmech.2010.08.050]

181. Korolyov A, Dorbes S, Azéma J, Guidetti B, Danel M, Lamoral-Theys D, Gras T, Dubois J, Kiss R, Martino R, Malet-Martino M..  (2010)  Novel lipophilic 7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid derivatives as potential antitumor agents: improved synthesis and in vitro evaluation.,  18  (24): [PMID:21067931] [10.1016/j.bmc.2010.10.039]

182. PubChem BioAssay data set, 

183. PubChem BioAssay data set, 

184. Obach RS, Lombardo F, Waters NJ..  (2008)  Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.,  36  (7): [PMID:18426954] [10.1124/dmd.108.020479]

185. Page S, Vernel-Pauillac F, O'Connor O, Bremont S, Charavay F, Courvalin P, Goarant C, Le Hello S..  (2008)  Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.,  52  (11): [PMID:18725440] [10.1128/aac.00082-08]

186. Credito K, Lin G, Koeth L, Sturgess MA, Appelbaum PC..  (2009)  Activity of levofloxacin alone and in combination with a DnaK inhibitor against gram-negative rods, including levofloxacin-resistant strains.,  53  (2): [PMID:19015359] [10.1128/aac.01132-08]

187. Jones CH, Tuckman M, Keeney D, Ruzin A, Bradford PA..  (2009)  Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.,  53  (2): [PMID:19015360] [10.1128/aac.00883-08]

188. Brown SD, Traczewski MM..  (2009)  In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.,  53  (3): [PMID:19114671] [10.1128/aac.01021-08]

189. Cui L, Neoh HM, Shoji M, Hiramatsu K..  (2009)  Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.,  53  (3): [PMID:19124662] [10.1128/aac.01173-08]

190. Morgan-Linnell SK, Becnel Boyd L, Steffen D, Zechiedrich L..  (2009)  Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates.,  53  (1): [PMID:18838592] [10.1128/aac.00665-08]

191. Becnel Boyd L, Maynard MJ, Morgan-Linnell SK, Horton LB, Sucgang R, Hamill RJ, Jimenez JR, Versalovic J, Steffen D, Zechiedrich L..  (2009)  Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.,  53  (1): [PMID:18838594] [10.1128/aac.00722-08]

192. Ma J, Zeng Z, Chen Z, Xu X, Wang X, Deng Y, Lü D, Huang L, Zhang Y, Liu J, Wang M..  (2009)  High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.,  53  (2): [PMID:18936192] [10.1128/aac.00886-08]

193. Biedenbach DJ, Bell JM, Sader HS, Turnidge JD, Jones RN..  (2009)  Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.,  53  (3): [PMID:19124664] [10.1128/aac.01453-08]

194. Petersen PJ, Jones CH, Venkatesan AM, Mansour TS, Projan SJ, Bradford PA..  (2009)  Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.,  53  (2): [PMID:19001109] [10.1128/aac.01047-08]

195. Tetz GV, Artemenko NK, Tetz VV..  (2009)  Effect of DNase and antibiotics on biofilm characteristics.,  53  (3): [PMID:19064900] [10.1128/aac.00471-08]

196. Hoban DJ, Bouchillon SK, Hawser SP, Badal RE, Labombardi VJ, DiPersio J..  (2010)  Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).,  54  (7): [PMID:20457818] [10.1128/aac.01808-09]

197. Baldoni D, Haschke M, Rajacic Z, Zimmerli W, Trampuz A..  (2009)  Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection.,  53  (3): [PMID:19075065] [10.1128/aac.00775-08]

198. Koga T, Sugihara C, Kakuta M, Masuda N, Namba E, Fukuoka T..  (2009)  Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.,  53  (3): [PMID:19104025] [10.1128/aac.01433-08]

199. Sabet M, Miller CE, Nolan TG, Senekeo-Effenberger K, Dudley MN, Griffith DC..  (2009)  Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa.,  53  (9): [PMID:19528273] [10.1128/aac.00268-09]

200. Sun W, Chen H, Liu Y, Zhao C, Nichols WW, Chen M, Zhang J, Ma Y, Wang H..  (2009)  Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.,  53  (9): [PMID:19546358] [10.1128/aac.00206-09]

201. Rukayadi Y, Lee K, Han S, Yong D, Hwang JK..  (2009)  In vitro activities of panduratin A against clinical Staphylococcus strains.,  53  (10): [PMID:19651906] [10.1128/aac.00624-09]

202. Koomanachai P, Crandon JL, Banevicius MA, Peng L, Nicolau DP..  (2009)  Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.,  53  (12): [PMID:19738006] [10.1128/aac.00985-09]

203. Rao SS, Raghunathan R, Ekambaram R, Raghunathan M..  (2009)  In vitro activity of a new quinoline derivative, ER-2, against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis.,  53  (12): [PMID:19738013] [10.1128/aac.00746-09]

204. Hamasuna R, Jensen JS, Osada Y..  (2009)  Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.,  53  (11): [PMID:19738019] [10.1128/aac.00724-09]

205. Arhin FF, Draghi DC, Pillar CM, Parr TR, Moeck G, Sahm DF..  (2009)  Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.,  53  (11): [PMID:19738026] [10.1128/aac.00952-09]

206. Nakao K, Tanaka K, Ichiishi S, Mikamo H, Shibata T, Watanabe K..  (2009)  Susceptibilities of 23 Desulfovibrio isolates from humans.,  53  (12): [PMID:19786606] [10.1128/aac.00630-09]

207. Cai Y, Li R, Liang B, Bai N, Liu Y, Wang R..  (2010)  In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii.,  54  (9): [PMID:20585134] [10.1128/aac.00264-10]

208. Biedenbach DJ, Castanheira M, Jones RN..  (2010)  Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection.,  54  (9): [PMID:20625152] [10.1128/aac.01812-09]

209. Saxton K, Baines SD, Freeman J, O'Connor R, Wilcox MH..  (2009)  Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model.,  53  (2): [PMID:18710908] [10.1128/aac.00306-08]

210. Suzuki H, Nishizawa T, Muraoka H, Hibi T..  (2009)  Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation.,  53  (4): [PMID:19188389] [10.1128/aac.00049-09]

211. Wagenlehner FM, Wagenlehner C, Redman R, Weidner W, Naber KG..  (2009)  Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis.,  53  (4): [PMID:19188391] [10.1128/aac.01133-08]

212. Wang M, Guo Q, Xu X, Wang X, Ye X, Wu S, Hooper DC, Wang M..  (2009)  New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis.,  53  (5): [PMID:19258263] [10.1128/aac.01400-08]

213. Waites KB, Crabb DM, Duffy LB..  (2009)  Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101.,  53  (5): [PMID:19258276] [10.1128/aac.00090-09]

214. Liu Y, Ye X, Zhang H, Xu X, Li W, Zhu D, Wang M..  (2009)  Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China.,  53  (5): [PMID:19273684] [10.1128/aac.01684-08]

215. Sader HS, Fritsche TR, Jones RN..  (2009)  Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates.,  53  (5): [PMID:19289528] [10.1128/aac.00129-09]

216. Kosowska-Shick K, Ednie LM, McGhee P, Appelbaum PC..  (2009)  Comparative antipneumococcal activities of sulopenem and other drugs.,  53  (6): [PMID:19307366] [10.1128/aac.01531-08]

217. Murayama SY, Seki C, Sakata H, Sunaoshi K, Nakayama E, Iwata S, Sunakawa K, Ubukata K, Invasive Streptococcal Disease Working Group..  (2009)  Capsular type and antibiotic resistance in Streptococcus agalactiae isolates from patients, ranging from newborns to the elderly, with invasive infections.,  53  (6): [PMID:19332682] [10.1128/aac.01716-08]

218. Vidaillac C, Leonard SN, Sader HS, Jones RN, Rybak MJ..  (2009)  In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.,  53  (6): [PMID:19349512] [10.1128/aac.01452-08]

219. Louie A, Fregeau C, Liu W, Kulawy R, Drusano GL..  (2009)  Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets.,  53  (8): [PMID:19364849] [10.1128/aac.00006-09]

220. Spigaglia P, Barbanti F, Louie T, Barbut F, Mastrantonio P..  (2009)  Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.,  53  (6): [PMID:19364867] [10.1128/aac.01252-08]

221. Pallecchi L, Riccobono E, Mantella A, Bartalesi F, Sennati S, Gamboa H, Gotuzzo E, Bartoloni A, Rossolini GM..  (2009)  High prevalence of qnr genes in commensal enterobacteria from healthy children in Peru and Bolivia.,  53  (6): [PMID:19364872] [10.1128/aac.01722-08]

222. Murakami K, Okimoto T, Kodama M, Tanahashi J, Fujioka T, Ikeda F, Muraoka H, Takigawa M, Saika T, Hasegawa M, Kobayashi I..  (2009)  Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations.,  53  (7): [PMID:19380599] [10.1128/aac.01552-08]

223. Ohtsuka M, Kikuchi K, Shimizu K, Takahashi N, Ono Y, Sasaki T, Hiramatsu K..  (2009)  Emergence of quinolone-resistant Bordetella pertussis in Japan.,  53  (7): [PMID:19414571] [10.1128/aac.00023-09]

224. Yamamoto K, Yanagihara K, Sugahara K, Imamura Y, Seki M, Izumikawa K, Kakeya H, Yamamoto Y, Hirakata Y, Kamihira S, Kohno S..  (2009)  In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.,  53  (8): [PMID:19451290] [10.1128/aac.00176-09]

225. Cerquetti M, García-Fernández A, Giufrè M, Fortini D, Accogli M, Graziani C, Luzzi I, Caprioli A, Carattoli A..  (2009)  First report of plasmid-mediated quinolone resistance determinant qnrS1 in an Escherichia coli strain of animal origin in Italy.,  53  (7): [PMID:19451298] [10.1128/aac.00239-09]

226. Karlowsky JA, Kaplan N, Hafkin B, Hoban DJ, Zhanel GG..  (2009)  AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.,  53  (8): [PMID:19487444] [10.1128/aac.00400-09]

227. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Hsueh PR, Paterson DL..  (2009)  Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.,  53  (8): [PMID:19506060] [10.1128/aac.00426-09]

228. Haas W, Pillar CM, Zurenko GE, Lee JC, Brunner LS, Morris TW..  (2009)  Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.,  53  (8): [PMID:19506065] [10.1128/aac.00418-09]

229. Zhang Y, Li G, Liu M, You X, Feng L, Lv K, Cao J, Guo H..  (2011)  Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-5-amino/methylaminopiperidin-1-yl)fluoroquinolone derivatives.,  21  (3): [PMID:21232952] [10.1016/j.bmcl.2010.12.073]

230. Liu JH, Deng YT, Zeng ZL, Gao JH, Chen L, Arakawa Y, Chen ZL..  (2008)  Coprevalence of plasmid-mediated quinolone resistance determinants QepA, Qnr, and AAC(6')-Ib-cr among 16S rRNA methylase RmtB-producing Escherichia coli isolates from pigs.,  52  (8): [PMID:18490500] [10.1128/aac.01686-07]

231. Tumbarello M, Sali M, Trecarichi EM, Leone F, Rossi M, Fiori B, De Pascale G, D'Inzeo T, Sanguinetti M, Fadda G, Cauda R, Spanu T..  (2008)  Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy.,  52  (9): [PMID:18591273] [10.1128/aac.00063-08]

232. Bratu S, Landman D, Martin DA, Georgescu C, Quale J..  (2008)  Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.,  52  (9): [PMID:18591275] [10.1128/aac.01684-07]

233. Ge Y, Biek D, Talbot GH, Sahm DF..  (2008)  In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.,  52  (9): [PMID:18625769] [10.1128/aac.00149-08]

234. Liu CY, Huang YT, Liao CH, Yen LC, Lin HY, Hsueh PR..  (2008)  Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.,  52  (9): [PMID:18625771] [10.1128/aac.00355-08]

235. Wehmeier C, Schuster S, Fähnrich E, Kern WV, Bohnert JA..  (2009)  Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.,  53  (1): [PMID:18936189] [10.1128/aac.00921-08]

236. Gunell M, Webber MA, Kotilainen P, Lilly AJ, Caddick JM, Jalava J, Huovinen P, Siitonen A, Hakanen AJ, Piddock LJ..  (2009)  Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.,  53  (9): [PMID:19596880] [10.1128/aac.00121-09]

237. Adam HJ, Laing NM, King CR, Lulashnyk B, Hoban DJ, Zhanel GG..  (2009)  In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.,  53  (11): [PMID:19738018] [10.1128/aac.00078-09]

238. Xu X, Cai L, Xiao M, Kong F, Oftadeh S, Zhou F, Gilbert GL..  (2010)  Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.,  54  (3): [PMID:20065057] [10.1128/aac.01268-09]

239. Goren MG, Navon-Venezia S, Chmelnitsky I, Carmeli Y..  (2010)  Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.,  54  (6): [PMID:20231393] [10.1128/aac.01359-09]

240. Jacobs MR, Good CE, Windau AR, Bajaksouzian S, Biek D, Critchley IA, Sader HS, Jones RN..  (2010)  Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.,  54  (6): [PMID:20308374] [10.1128/aac.01797-09]

241. McDougal LK, Fosheim GE, Nicholson A, Bulens SN, Limbago BM, Shearer JE, Summers AO, Patel JB..  (2010)  Emergence of resistance among USA300 methicillin-resistant Staphylococcus aureus isolates causing invasive disease in the United States.,  54  (9): [PMID:20585117] [10.1128/aac.00351-10]

242. Butler MM, Williams JD, Peet NP, Moir DT, Panchal RG, Bavari S, Shinabarger DL, Bowlin TL..  (2010)  Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.,  54  (9): [PMID:20625154] [10.1128/aac.00484-10]

243. Nelson M, Lever MS, Dean RE, Pearce PC, Stevens DJ, Simpson AJ..  (2010)  Bioavailability and efficacy of levofloxacin against Francisella tularensis in the common marmoset (Callithrix jacchus).,  54  (9): [PMID:20625157] [10.1128/aac.00390-10]

244. Nakaminami H, Noguchi N, Sasatsu M..  (2010)  Fluoroquinolone efflux by the plasmid-mediated multidrug efflux pump QacB variant QacBIII in Staphylococcus aureus.,  54  (10): [PMID:20660673] [10.1128/aac.01065-09]

245. Singh R, Ledesma KR, Chang KT, Tam VH..  (2010)  Impact of recA on levofloxacin exposure-related resistance development.,  54  (10): [PMID:20660686] [10.1128/aac.00168-10]

246. Su HC, Ramkissoon K, Doolittle J, Clark M, Khatun J, Secrest A, Wolfgang MC, Giddings MC..  (2010)  The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.,  54  (11): [PMID:20696867] [10.1128/aac.00762-10]

247. Sun JR, Chan MC, Chang TY, Wang WY, Chiueh TS..  (2010)  Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.,  54  (11): [PMID:20696871] [10.1128/aac.00414-10]

248. Khanna A, Raj VS, Tarai B, Sood R, Pareek PK, Upadhyay DJ, Sharma P, Rattan A, Saini KS, Singh H..  (2010)  Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.,  54  (11): [PMID:20713679] [10.1128/aac.00661-10]

249. Donati M, Di Francesco A, D'Antuono A, Delucca F, Shurdhi A, Moroni A, Baldelli R, Cevenini R..  (2010)  In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K.,  54  (12): [PMID:20855744] [10.1128/aac.00553-10]

250. Murillo O, Pachón ME, Euba G, Verdaguer R, Tubau F, Cabellos C, Cabo J, Gudiol F, Ariza J..  (2008)  Antagonistic effect of rifampin on the efficacy of high-dose levofloxacin in staphylococcal experimental foreign-body infection.,  52  (10): [PMID:18676888] [10.1128/aac.00458-08]

251. Naber KG, Llorens L, Kaniga K, Kotey P, Hedrich D, Redman R..  (2009)  Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis.,  53  (9): [PMID:19581455] [10.1128/aac.00837-08]

252. Bialek S, Lavigne JP, Chevalier J, Marcon E, Leflon-Guibout V, Davin A, Moreau R, Pagès JM, Nicolas-Chanoine MH..  (2010)  Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.,  54  (10): [PMID:20679507] [10.1128/aac.01607-09]

253. Malik M, Marks KR, Schwanz HA, German N, Drlica K, Kerns RJ..  (2010)  Effect of N-1/c-8 ring fusion and C-7 ring structure on fluoroquinolone lethality.,  54  (12): [PMID:20855738] [10.1128/aac.01054-10]

254. Higgins PG, Schneiders T, Hamprecht A, Seifert H..  (2010)  In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.,  54  (12): [PMID:20921306] [10.1128/aac.00598-10]

255. Briales A, Rodríguez-Martínez JM, Velasco C, Díaz de Alba P, Domínguez-Herrera J, Pachón J, Pascual A..  (2011)  In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.,  55  (3): [PMID:21173174] [10.1128/aac.00927-10]

256. Lowe R, Glen RC, Mitchell JB..  (2010)  Predicting phospholipidosis using machine learning.,  7  (5): [PMID:20799726] [10.1021/mp100103e]

257. Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ..  (2010)  Developing structure-activity relationships for the prediction of hepatotoxicity.,  23  (7): [PMID:20553011] [10.1021/tx1000865]

258. Ekins S, Williams AJ, Xu JJ..  (2010)  A predictive ligand-based Bayesian model for human drug-induced liver injury.,  38  (12): [PMID:20843939] [10.1124/dmd.110.035113]

259. Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A..  (2010)  Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.,  23  (1): [PMID:20014752] [10.1021/tx900326k]

260. Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF..  (2004)  Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.,  1  (4): [PMID:16472241] [10.2174/1570163043334794]

261. Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancilio LF..  (2008)  Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.,  18  (2): [PMID:20020916] [10.1080/15376510701857262]

262. International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L..  (2010)  Membrane transporters in drug development.,  9  (3): [PMID:20190787] [10.1038/nrd3028]

263. Al-Trawneh SA, El-Abadelah MM, Zahra JA, Al-Taweel SA, Zani F, Incerti M, Cavazzoni A, Vicini P..  (2011)  Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.,  19  (8): [PMID:21458275] [10.1016/j.bmc.2011.03.018]

264. Kim HY, Wiles JA, Wang Q, Pais GC, Lucien E, Hashimoto A, Nelson DM, Thanassi JA, Podos SD, Deshpande M, Pucci MJ, Bradbury BJ..  (2011)  Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).,  54  (9): [PMID:21425851] [10.1021/jm101604v]

265. Chai Y, Wang J, Liu M, Yi H, Sun L, You X, Guo H..  (2011)  Design, synthesis and in vitro antibacterial activity of 7-(4-alkoxyimino-3-aminomethylpiperidin-1-yl)fluoroquinolone derivatives.,  21  (11): [PMID:21515052] [10.1016/j.bmcl.2011.04.002]

266. Wang JX, Zhang YB, Liu ML, Wang B, Chai Y, Li SJ, Guo HY..  (2011)  Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives.,  46  (6): [PMID:21481984] [10.1016/j.ejmech.2011.03.026]

267. Fridén M, Winiwarter S, Jerndal G, Bengtsson O, Wan H, Bredberg U, Hammarlund-Udenaes M, Antonsson M..  (2009)  Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.,  52  (20): [PMID:19764786] [10.1021/jm901036q]

268. Gan M, Zheng X, Gan L, Guan Y, Hao X, Liu Y, Si S, Zhang Y, Yu L, Xiao C..  (2011)  Streptothricin derivatives from Streptomyces sp. I08A 1776.,  74  (5): [PMID:21510638] [10.1021/np2000733]

269. Liu J, Li F, Kim EL, Li JL, Hong J, Bae KS, Chung HY, Kim HS, Jung JH..  (2011)  Antibacterial polyketides from the jellyfish-derived fungus Paecilomyces variotii.,  74  (8): [PMID:21744790] [10.1021/np200350b]

270. Chai Y, Liu ML, Lv K, Feng LS, Li SJ, Sun LY, Wang S, Guo HY..  (2011)  Synthesis and in vitro antibacterial activity of a series of novel gatifloxacin derivatives.,  46  (9): [PMID:21764484] [10.1016/j.ejmech.2011.06.032]

271. Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program. DrugMatrix in vitro pharmacology data, 

272. Azéma J, Guidetti B, Korolyov A, Kiss R, Roques C, Constant P, Daffé M, Malet-Martino M..  (2011)  Synthesis of lipophilic dimeric C-7/C-7-linked ciprofloxacin and C-6/C-6-linked levofloxacin derivatives. Versatile in vitro biological evaluations of monomeric and dimeric fluoroquinolone derivatives as potential antitumor, antibacterial or antimycobacterial agents.,  46  (12): [PMID:22036229] [10.1016/j.ejmech.2011.10.014]

273. Reck F, Alm R, Brassil P, Newman J, Dejonge B, Eyermann CJ, Breault G, Breen J, Comita-Prevoir J, Cronin M, Davis H, Ehmann D, Galullo V, Geng B, Grebe T, Morningstar M, Walker P, Hayter B, Fisher S..  (2011)  Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: broad-spectrum antibacterial agents with reduced hERG activity.,  54  (22): [PMID:21999508] [10.1021/jm2008826]

274. Clark RB, Hunt DK, He M, Achorn C, Chen CL, Deng Y, Fyfe C, Grossman TH, Hogan PC, O'Brien WJ, Plamondon L, Rönn M, Sutcliffe JA, Zhu Z, Xiao XY..  (2012)  Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.,  55  (2): [PMID:22148555] [10.1021/jm201467r]

275. Manchester JI, Dussault DD, Rose JA, Boriack-Sjodin PA, Uria-Nickelsen M, Ioannidis G, Bist S, Fleming P, Hull KG..  (2012)  Discovery of a novel azaindole class of antibacterial agents targeting the ATPase domains of DNA gyrase and Topoisomerase IV.,  22  (15): [PMID:22814212] [10.1016/j.bmcl.2012.05.128]

276. Feng L, Lv K, Liu M, Wang S, Zhao J, You X, Li S, Cao J, Guo H..  (2012)  Synthesis and in vitro antibacterial activity of gemifloxacin derivatives containing a substituted benzyloxime moiety.,  55  [PMID:22841282] [10.1016/j.ejmech.2012.07.010]

277. Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE..  (2012)  Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.,  25  (10): [PMID:22931300] [10.1021/tx300075j]

278. Yamaguchi H, Yano I, Saito H, Inui K..  (2004)  Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats.,  21  (1): [PMID:15032316] [10.1023/b:pham.0000016247.44589.f1]

279. Ito T, Yano I, Tanaka K, Inui KI..  (1997)  Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1.,  282  (1): [PMID:9262363]

280. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A..  (1999)  Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations.,  289  (1): [PMID:10215651]

281. Yamaguchi H, Yano I, Hashimoto Y, Inui KI..  (2000)  Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line caco-2.,  295  (1): [PMID:10992002]

282. Okuda M, Urakami Y, Saito H, Inui K..  (1999)  Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes.,  1417  (1): [PMID:10082798] [10.1016/s0005-2736(99)00005-x]

283. Urakami Y, Akazawa M, Saito H, Okuda M, Inui K..  (2002)  cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney.,  13  (1): [PMID:12089365] [10.1097/01.asn.0000019413.78751.46]

284. Uwai Y, Okuda M, Takami K, Hashimoto Y, Inui K..  (1998)  Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney.,  438  (1): [PMID:9827570] [10.1016/s0014-5793(98)01328-3]

285. Gan M, Zheng X, Liu Y, Guan Y, Xiao C..  (2012)  Three new 12-carbamoylated streptothricins from Streptomyces sp. I08A 1776.,  22  (19): [PMID:22939698] [10.1016/j.bmcl.2012.08.003]

286. Shou Q, Banbury LK, Renshaw DE, Lambley EH, Mon H, Macfarlane GA, Griesser HJ, Heinrich MM, Wohlmuth H..  (2012)  Biologically active dibenzofurans from Pilidiostigma glabrum, an endemic Australian Myrtaceae.,  75  (9): [PMID:22934671] [10.1021/np300433r]

287. Cormier R, Burda WN, Harrington L, Edlinger J, Kodigepalli KM, Thomas J, Kapolka R, Roma G, Anderson BE, Turos E, Shaw LN..  (2012)  Studies on the antimicrobial properties of N-acylated ciprofloxacins.,  22  (20): [PMID:22995622] [10.1016/j.bmcl.2012.05.026]

288. Reck F, Alm RA, Brassil P, Newman JV, Ciaccio P, McNulty J, Barthlow H, Goteti K, Breen J, Comita-Prevoir J, Cronin M, Ehmann DE, Geng B, Godfrey AA, Fisher SL..  (2012)  Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profile.,  55  (15): [PMID:22779424] [10.1021/jm300690s]

289. Gerusz V, Denis A, Faivre F, Bonvin Y, Oxoby M, Briet S, LeFralliec G, Oliveira C, Desroy N, Raymond C, Peltier L, Moreau F, Escaich S, Vongsouthi V, Floquet S, Drocourt E, Walton A, Prouvensier L, Saccomani M, Durant L, Genevard JM, Sam-Sambo V, Soulama-Mouze C..  (2012)  From triclosan toward the clinic: discovery of nonbiocidal, potent FabI inhibitors for the treatment of resistant bacteria.,  55  (22): [PMID:23092194] [10.1021/jm301113w]

290. Martínez-Botella G, Breen JN, Duffy JE, Dumas J, Geng B, Gowers IK, Green OM, Guler S, Hentemann MF, Hernandez-Juan FA, Joseph-McCarthy D, Kawatkar S, Larsen NA, Lazari O, Loch JT, Macritchie JA, McKenzie AR, Newman JV, Olivier NB, Otterson LG, Owens AP, Read J, Sheppard DW, Keating TA..  (2012)  Discovery of selective and potent inhibitors of gram-positive bacterial thymidylate kinase (TMK).,  55  (22): [PMID:23043329] [10.1021/jm3011806]

291. Aytemir MD, Ozcelik B.  (2011)  Synthesis and biological activities of new Mannich bases of chlorokojic acid derivatives,  20  (4): [10.1007/s00044-010-9338-x]

292. Wu J, Wang C, Cai Y, Peng J, Liang D, Zhao Y, Yang S, Li X, Wu X, Liang G.  (2012)  Synthesis and crystal structure of chalcones as well as on cytotoxicity and antibacterial properties,  21  (4): [10.1007/s00044-011-9549-9]

293. Emami S, Shahrokhirad N, Foroumadi A, Faramarzi MA, Samadi N, Soltani-Ghofrani N.  (2013)  7-Piperazinylquinolones with methylene-bridged nitrofuran scaffold as new antibacterial agents,  22  (12): [10.1007/s00044-013-0581-9]

294. Asif M, Siddiqui AA, Husain A.  (2013)  Quinolone derivatives as antitubercular drugs,  22  (3): [10.1007/s00044-012-0101-3]

295. Liu J, Wu F, Song H, Wang Z, Zhao L.  (2013)  Synthesis and antibacterial activities of para-alkoxy phenyl--ketoaldehyde derivatives,  22  (9): [10.1007/s00044-012-0429-8]

296. Zhao D, Liu H, Zheng L, He G, Qu D, Han S.  (2013)  Synthesis of novel 4-thiazolidione derivatives as antibacterial agents against drug-resistant Staphylococcus epidermidis,  22  (8): [10.1007/s00044-012-0363-9]

297. Wittwer MB, Zur AA, Khuri N, Kido Y, Kosaka A, Zhang X, Morrissey KM, Sali A, Huang Y, Giacomini KM..  (2013)  Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.,  56  (3): [PMID:23241029] [10.1021/jm301302s]

298. Xu HW, Xu C, Fan ZQ, Zhao LJ, Liu HM..  (2013)  A facile synthesis, antibacterial activity of pulvinone and its derivatives.,  23  (3): [PMID:23265890] [10.1016/j.bmcl.2012.11.090]

299. Odagiri T, Inagaki H, Sugimoto Y, Nagamochi M, Miyauchi RN, Kuroyanagi J, Kitamura T, Komoriya S, Takahashi H..  (2013)  Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.,  56  (5): [PMID:23409972] [10.1021/jm301650g]

300. Martínez-Botella G, Loch JT, Green OM, Kawatkar SP, Olivier NB, Boriack-Sjodin PA, Keating TA..  (2013)  Sulfonylpiperidines as novel, antibacterial inhibitors of Gram-positive thymidylate kinase (TMK).,  23  (1): [PMID:23206863] [10.1016/j.bmcl.2012.10.128]

301. Lv K, Wu J, Wang J, Liu M, Wei Z, Cao J, Sun Y, Guo H..  (2013)  Synthesis and in vitro antibacterial activity of quinolone/naphthyridone derivatives containing 3-alkoxyimino-4-(methyl)aminopiperidine scaffolds.,  23  (6): [PMID:23402878] [10.1016/j.bmcl.2013.01.048]

302. Ryu S, Imai YN, Oiki S..  (2013)  The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.,  23  (13): [PMID:23711922] [10.1016/j.bmcl.2013.04.074]

303. Ren JL, Zhang E, Ye XW, Wang MM, Yu B, Wang WH, Guo YZ, Liu HM..  (2013)  Design, synthesis and antibacterial evaluation of novel AHL analogues.,  23  (14): [PMID:23735742] [10.1016/j.bmcl.2013.05.035]

304. Zuo G, Li Y, Wang G, Li Z, Han J.  (2013)  Synergistic effects of berberines with antibiotics on clinical multi-drug resistant isolates of methicillin-resistant Staphylococcus aureus (MRSA),  [10.1007/s00044-013-0844-5]

305. Settimo L, Bellman K, Knegtel RM..  (2013)  Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.,  [PMID:24249037] [10.1007/s11095-013-1232-z]

306. De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP..  (2013)  Structure-based identification of OATP1B1/3 inhibitors.,  83  (6): [PMID:23571415] [10.1124/mol.112.084152]

307. Zhang QR, Xue DQ, He P, Shao KP, Chen PJ, Gu YF, Ren JL, Shan LH, Liu HM..  (2014)  Synthesis and antimicrobial activities of novel 1,2,4-triazolo [3,4-a] phthalazine derivatives.,  24  (4): [PMID:24447849] [10.1016/j.bmcl.2013.12.010]

308. Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R..  (2004)  [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].,  28  (8-9): [PMID:15646539] [10.1016/s0399-8320(04)95062-2]

309. Kigondu EM, Njoroge M, Singh K, Njuguna N, Warner DF, Chibale K.  (2014)  Synthesis and synergistic antimycobacterial screening of chlorpromazine and its metabolites,  5  (4): [10.1039/C3MD00387F]

310. Niu S, Liu D, Hu X, Proksch P, Shao Z, Lin W..  (2014)  Spiromastixones A-O, antibacterial chlorodepsidones from a deep-sea-derived Spiromastix sp. fungus.,  77  (4): [PMID:24571273] [10.1021/np5000457]

311. Basarab GS, Manchester JI, Bist S, Boriack-Sjodin PA, Dangel B, Illingworth R, Sherer BA, Sriram S, Uria-Nickelsen M, Eakin AE..  (2013)  Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.,  56  (21): [PMID:24098982] [10.1021/jm401208b]

312. Zorzi RR, Jorge SD, Palace-Berl F, Pasqualoto KF, Bortolozzo Lde S, de Castro Siqueira AM, Tavares LC..  (2014)  Exploring 5-nitrofuran derivatives against nosocomial pathogens: synthesis, antimicrobial activity and chemometric analysis.,  22  (10): [PMID:24751553] [10.1016/j.bmc.2014.03.044]

313. Tseng YY, Liou JM, Hsu TL, Cheng WC, Wu MS, Wong CH..  (2014)  Development of bacterial transglycosylase inhibitors as new antibiotics: moenomycin A treatment for drug-resistant Helicobacter pylori.,  24  (11): [PMID:24775303] [10.1016/j.bmcl.2014.04.041]

314. Ferretti MD, Neto AT, Morel AF, Kaufman TS, Larghi EL..  (2014)  Synthesis of symmetrically substituted 3,3-dibenzyl-4-hydroxy-3,4-dihydro-1H-quinolin-2-ones, as novel quinoline derivatives with antibacterial activity.,  81  [PMID:24852274] [10.1016/j.ejmech.2014.05.024]

315. Chen PJ, Yang A, Gu YF, Zhang XS, Shao KP, Xue DQ, He P, Jiang TF, Zhang QR, Liu HM..  (2014)  Synthesis, in vitro antimicrobial and cytotoxic activities of novel pyrimidine-benzimidazol combinations.,  24  (12): [PMID:24798098] [10.1016/j.bmcl.2014.04.037]

316. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

317. Basarab GS, Hill PJ, Garner CE, Hull K, Green O, Sherer BA, Dangel PB, Manchester JI, Bist S, Hauck S, Zhou F, Uria-Nickelsen M, Illingworth R, Alm R, Rooney M, Eakin AE..  (2014)  Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099).,  57  (14): [PMID:24959892] [10.1021/jm500462x]

318. Reck F, Ehmann DE, Dougherty TJ, Newman JV, Hopkins S, Stone G, Agrawal N, Ciaccio P, McNulty J, Barthlow H, O'Donnell J, Goteti K, Breen J, Comita-Prevoir J, Cornebise M, Cronin M, Eyermann CJ, Geng B, Carr GR, Pandarinathan L, Tang X, Cottone A, Zhao L, Bezdenejnih-Snyder N..  (2014)  Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa.,  22  (19): [PMID:25155913] [10.1016/j.bmc.2014.07.040]

319. Basarab GS, Brassil P, Doig P, Galullo V, Haimes HB, Kern G, Kutschke A, McNulty J, Schuck VJ, Stone G, Gowravaram M..  (2014)  Novel DNA gyrase inhibiting spiropyrimidinetriones with a benzisoxazole scaffold: SAR and in vivo characterization.,  57  (21): [PMID:25286019] [10.1021/jm501174m]

320. Liu H, Huang J, Wang J, Wang M, Liu M, Wang B, Guo H, Lu Y..  (2014)  Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.,  86  [PMID:25218911] [10.1016/j.ejmech.2014.09.029]

321. Nguyen ST, Kwasny SM, Ding X, Cardinale SC, McCarthy CT, Kim HS, Nikaido H, Peet NP, Williams JD, Bowlin TL, Opperman TJ..  (2015)  Structure-activity relationships of a novel pyranopyridine series of Gram-negative bacterial efflux pump inhibitors.,  23  (9): [PMID:25818767] [10.1016/j.bmc.2015.03.016]

322. Singh SB, Kaelin DE, Wu J, Miesel L, Tan CM, Black T, Nargund R, Meinke PT, Olsen DB, Lagrutta A, Lu J, Patel S, Rickert KW, Smith RF, Soisson S, Sherer E, Joyce LA, Wei C, Peng X, Wang X, Fukuda H, Kishii R, Takei M, Takano H, Shibasaki M, Yajima M, Nishimura A, Shibata T, Fukuda Y..  (2015)  Tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of left-hand-side moiety (Part-2).,  25  (9): [PMID:25851938] [10.1016/j.bmcl.2015.03.044]

323. Singh SB, Kaelin DE, Wu J, Miesel L, Tan CM, Meinke PT, Olsen DB, Lagrutta A, Wei C, Peng X, Wang X, Fukuda H, Kishii R, Takei M, Shibata T, Ohata K, Takano H, Kurasaki H, Takeuchi T, Nishimura A, Fukuda Y..  (2015)  Structure activity relationship of substituted 1,5-naphthyridine analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-4).,  25  (11): [PMID:25911300] [10.1016/j.bmcl.2015.04.002]

324. Singh SB, Kaelin DE, Wu J, Miesel L, Tan CM, Gill C, Black T, Nargund R, Meinke PT, Olsen DB, Lagrutta A, Wei C, Peng X, Wang X, Fukuda H, Kishii R, Takei M, Takeuchi T, Shibue T, Ohata K, Takano H, Ban S, Nishimura A, Fukuda Y..  (2015)  Hydroxy tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of RHS moiety (Part-3).,  25  (12): [PMID:25978963] [10.1016/j.bmcl.2015.04.063]

325. Fridén M, Bergström F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M, Bredberg U..  (2011)  Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.,  39  (3): [PMID:21149540] [10.1124/dmd.110.035998]

326. Nakayama S, Takakusa H, Watanabe A, Miyaji Y, Suzuki W, Sugiyama D, Shiosakai K, Honda K, Okudaira N, Izumi T, Okazaki O..  (2011)  Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,  39  (7): [PMID:21467212] [10.1124/dmd.111.039180]

327. Dawson S, Stahl S, Paul N, Barber J, Kenna JG..  (2012)  In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.,  40  (1): [PMID:21965623] [10.1124/dmd.111.040758]

328. Sun X, Sun S, Ference C, Zhu W, Zhou N, Zhang Y, Zhou K..  (2015)  A potent antimicrobial compound isolated from Clathria cervicornis.,  25  (1): [PMID:25435146] [10.1016/j.bmcl.2014.11.012]

329. Whalen KE, Poulson-Ellestad KL, Deering RW, Rowley DC, Mincer TJ..  (2015)  Enhancement of antibiotic activity against multidrug-resistant bacteria by the efflux pump inhibitor 3,4-dibromopyrrole-2,5-dione isolated from a Pseudoalteromonas sp.,  78  (3): [PMID:25646964] [10.1021/np500775e]

330. Sun C, Hunt DK, Chen CL, Deng Y, He M, Clark RB, Fyfe C, Grossman TH, Sutcliffe JA, Xiao XY..  (2015)  Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents.,  58  (11): [PMID:25927406] [10.1021/acs.jmedchem.5b00262]

331. Singh SB, Kaelin DE, Meinke PT, Wu J, Miesel L, Tan CM, Olsen DB, Lagrutta A, Fukuda H, Kishii R, Takei M, Takeuchi T, Takano H, Ohata K, Kurasaki H, Nishimura A, Shibata T, Fukuda Y..  (2015)  Structure activity relationship of C-2 ether substituted 1,5-naphthyridine analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-5).,  25  (17): [PMID:26152426] [10.1016/j.bmcl.2015.06.061]

332. Koh JJ, Lin H, Caroline V, Chew YS, Pang LM, Aung TT, Li J, Lakshminarayanan R, Tan DT, Verma C, Tan AL, Beuerman RW, Liu S..  (2015)  N-Lipidated Peptide Dimers: Effective Antibacterial Agents against Gram-Negative Pathogens through Lipopolysaccharide Permeabilization.,  58  (16): [PMID:26214729] [10.1021/acs.jmedchem.5b00628]

333. Sashidhara KV, Rao KB, Kushwaha P, Modukuri RK, Singh P, Soni I, Shukla PK, Chopra S, Pasupuleti M..  (2015)  Novel Chalcone-Thiazole Hybrids as Potent Inhibitors of Drug Resistant Staphylococcus aureus.,  6  (7): [PMID:26191371] [10.1021/acsmedchemlett.5b00169]

334. O'Dowd H, Shannon DE, Chandupatla KR, Dixit V, Engtrakul JJ, Ye Z, Jones SM, O'Brien CF, Nicolau DP, Tessier PR, Crandon JL, Song B, Macikenas D, Hanzelka BL, Le Tiran A, Bennani YL, Charifson PS, Grillot AL..  (2015)  Discovery and Characterization of a Water-Soluble Prodrug of a Dual Inhibitor of Bacterial DNA Gyrase and Topoisomerase IV.,  6  (7): [PMID:26191374] [10.1021/acsmedchemlett.5b00196]

335. Huang X, Bao Y, Zhu S, Zhang X, Lan S, Wang T..  (2015)  Synthesis and biological evaluation of levofloxacin core-based derivatives with potent antibacterial activity against resistant Gram-positive pathogens.,  25  (18): [PMID:26238324] [10.1016/j.bmcl.2015.07.044]

336. Gan M, Liu B, Tan Y, Wang Q, Zhou H, He H, Ping Y, Yang Z, Wang Y, Xiao C..  (2015)  Saccharothrixones A-D, Tetracenomycin-Type Polyketides from the Marine-Derived Actinomycete Saccharothrix sp. 10-10.,  78  (9): [PMID:26317881] [10.1021/acs.jnatprod.5b00577]

337. Bansal S, Singh M, Kidwai S, Bhargava P, Singh A, Sreekanth V, Singh R, Bajaj A.  (2014)  Bile acid amphiphiles with tunable head groups as highly selective antitubercular agents,  5  (11): [10.1039/C4MD00303A]

338. Itoh K, Kuramoto Y, Amano H, Kazamori D, Yazaki A..  (2015)  Discovery of WQ-3810: Design, synthesis, and evaluation of 7-(3-alkylaminoazetidin-1-yl)fluoro-quinolones as orally active antibacterial agents.,  103  [PMID:26363871] [10.1016/j.ejmech.2015.08.015]

339. Li J, Sui YP, Xin JJ, Du XL, Li JT, Huo HR, Ma H, Wang WH, Zhou HY, Zhan HD, Wang ZJ, Li C, Sui F, Li X..  (2015)  Synthesis of biscoumarin and dihydropyran derivatives with promising antitumor and antibacterial activities.,  25  (23): [PMID:26522947] [10.1016/j.bmcl.2015.10.063]

340. Huang J, Liu H, Liu M, Zhang R, Li L, Wang B, Wang M, Wang C, Lu Y..  (2015)  Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.,  25  (22): [PMID:26476970] [10.1016/j.bmcl.2015.10.027]

341. MMV Pathogen Box,  [10.6019/CHEMBL3637841]

342. Zhang T, Shen W, Liu M, Zhang R, Wang M, Li L, Wang B, Guo H, Lu Y..  (2015)  Synthesis, antimycobacterial and antibacterial activity of fluoroquinolone derivatives containing an 3-alkoxyimino-4-(cyclopropylanimo)methylpyrrolidine moiety.,  104  [PMID:26435513] [10.1016/j.ejmech.2015.09.030]

343. Singh SB, Kaelin DE, Wu J, Miesel L, Tan CM, Meinke PT, Olsen DB, Lagrutta A, Wei C, Liao Y, Peng X, Wang X, Fukuda H, Kishii R, Takei M, Shibata T, Takeuchi T, Ohata K, Nishimura A, Fukuda Y.  (2015)  C1C2-linker substituted 1,5-naphthyridine analogues of oxabicyclooctane-linked NBTIs as broad-spectrum antibacterial agents (part 7),  6  (10): [10.1039/C5MD00297D]

344. Mon HH, Christo SN, Ndi CP, Jasieniak M, Rickard H, Hayball JD, Griesser HJ, Semple SJ..  (2015)  Serrulatane Diterpenoid from Eremophila neglecta Exhibits Bacterial Biofilm Dispersion and Inhibits Release of Pro-inflammatory Cytokines from Activated Macrophages.,  78  (12): [PMID:26636180] [10.1021/acs.jnatprod.5b00833]

345. Dahdouh E, Orgaz B, Gomez-Gil R, Mingorance J, Daoud Z, Suarez M, San Jose C.  (2016)  Patterns of biofilm structure and formation kinetics among Acinetobacter baumannii clinical isolates with different antibiotic resistance profiles,  7  (1): [10.1039/C5MD00377F]

346. Huang J, Wang M, Wang B, Wu Z, Liu M, Feng L, Zhang J, Li X, Yang Y, Lu Y..  (2016)  Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.,  26  (9): [PMID:27020299] [10.1016/j.bmcl.2016.03.050]

347. Lv F, Chen C, Tang Y, Wei J, Zhu T, Hu W..  (2016)  New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment.,  26  (15): [PMID:27293070] [10.1016/j.bmcl.2016.05.077]

348. Pawar CD, Sarkate AP, Karnik KS, Bahekar SS, Pansare DN, Shelke RN, Jawale CS, Shinde DB..  (2016)  Synthesis and antimicrobial evaluation of novel ethyl 2-(2-(4-substituted)acetamido)-4-subtituted-thiazole-5-carboxylate derivatives.,  26  (15): [PMID:27324976] [10.1016/j.bmcl.2016.06.030]

349. Tanaka SK, Steenbergen J, Villano S..  (2016)  Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.,  24  (24): [PMID:27469981] [10.1016/j.bmc.2016.07.029]

350. DrugMatrix,  [10.6019/CHEMBL3885881]

351. DailyMed|setid=8962eb50-3366-1eec-44f9-170e686d2d66 | LEVOFLOXACIN - levofloxacin tablet, film coated|Jubilant Cadista Pharmaceuticals Inc., 

352. Anna Ehmann. The Australian National University Dept Of Immunology Pathogen Box Compounds Screened,  [10.6019/CHEMBL3987221]

353. Vajs J, Proud C, Brozovic A, Gazvoda M, Lloyd A, Roper DI, Osmak M, Košmrlj J, Dowson CG..  (2017)  Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis.,  127  [PMID:28063354] [10.1016/j.ejmech.2016.12.060]

354. Chen X, Hu X, Wu Y, Liu Y, Bian C, Nie T, You X, Hu L..  (2017)  Synthesis and in vitro activity of dicationic indolyl diphenyl ethers as novel potent antibiotic agents against drug-resistant bacteria.,  27  (4): [PMID:28109787] [10.1016/j.bmcl.2017.01.019]

355. Lin S, Koh JJ, Aung TT, Sin WLW, Lim F, Wang L, Lakshminarayanan R, Zhou L, Tan DTH, Cao D, Beuerman RW, Ren L, Liu S..  (2017)  Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).,  60  (14): [PMID:28636355] [10.1021/acs.jmedchem.7b00380]

356. Picconi P, Hind C, Jamshidi S, Nahar K, Clifford M, Wand ME, Sutton JM, Rahman KM..  (2017)  Triaryl Benzimidazoles as a New Class of Antibacterial Agents against Resistant Pathogenic Microorganisms.,  60  (14): [PMID:28650661] [10.1021/acs.jmedchem.7b00108]

357. Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T..  (2012)  Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.,  40  (12): [PMID:22961681] [10.1124/dmd.112.047068]

358. Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK..  (2013)  A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,  136  (1): [PMID:23956101] [10.1093/toxsci/kft176]

359. Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W..  (2016)  DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.,  21  (4): [PMID:26948801] [10.1016/j.drudis.2016.02.015]

360. Hussain A, Rather MA, Dar MS, Aga MA, Ahmad N, Manzoor A, Qayum A, Shah A, Mushtaq S, Ahmad Z, Hassan QP..  (2017)  Novel bioactive molecules from Lentzea violacea strain AS 08 using one strain-many compounds (OSMAC) approach.,  27  (11): [PMID:28400238] [10.1016/j.bmcl.2017.03.075]

361. Wilson CR, Gessner RK, Moosa A, Seldon R, Warner DF, Mizrahi V, Soares de Melo C, Simelane SB, Nchinda A, Abay E, Taylor D, Njoroge M, Brunschwig C, Lawrence N, Boshoff HIM, Barry CE, Sirgel FA, van Helden P, Harris CJ, Gordon R, Ghidelli-Disse S, Pflaumer H, Boesche M, Drewes G, Sanz O, Santos G, Rebollo-Lopez MJ, Urones B, Selenski C, Lafuente-Monasterio MJ, Axtman M, Lelièvre J, Ballell L, Mueller R, Street LJ, Ghorpade SR, Chibale K..  (2017)  Novel Antitubercular 6-Dialkylaminopyrimidine Carboxamides from Phenotypic Whole-Cell High Throughput Screening of a SoftFocus Library: Structure-Activity Relationship and Target Identification Studies.,  60  (24): [PMID:29148755] [10.1021/acs.jmedchem.7b01347]

362. Lu X, Tang J, Cui S, Wan B, Franzblauc SG, Zhang T, Zhang X, Ding K..  (2017)  Pyrazolo[1,5-a]pyridine-3-carboxamide hybrids: Design, synthesis and evaluation of anti-tubercular activity.,  125  [PMID:27654393] [10.1016/j.ejmech.2016.09.030]

363. Reyes-Melo K, García A, Romo-Mancillas A, Garza-González E, Rivas-Galindo VM, Miranda LD, Vargas-Villarreal J, Favela-Hernández JMJ, Camacho-Corona MDR..  (2017)  meso-Dihydroguaiaretic acid derivatives with antibacterial and antimycobacterial activity.,  25  (20): [PMID:28844400] [10.1016/j.bmc.2017.07.047]

364. Mason DJ, Stott I, Ashenden S, Weinstein ZB, Karakoc I, Meral S, Kuru N, Bender A, Cokol M..  (2017)  Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure.,  60  (9): [PMID:28383902] [10.1021/acs.jmedchem.7b00204]

365. Lin S, Koh JJ, Aung TT, Lim F, Li J, Zou H, Wang L, Lakshminarayanan R, Verma C, Wang Y, Tan DT, Cao D, Beuerman RW, Ren L, Liu S..  (2017)  Symmetrically Substituted Xanthone Amphiphiles Combat Gram-Positive Bacterial Resistance with Enhanced Membrane Selectivity.,  60  (4): [PMID:28122182] [10.1021/acs.jmedchem.6b01403]

366. Papadopoulou MV, Bloomer WD, Rosenzweig HS, Kaiser M..  (2017)  The antitrypanosomal and antitubercular activity of some nitro(triazole/imidazole)-based aromatic amines.,  138  [PMID:28763645] [10.1016/j.ejmech.2017.07.060]

367. Deshmukh MS, Jain N..  (2017)  Design, Synthesis, and Antibacterial Evaluation of Oxazolidinones with Fused Heterocyclic C-Ring Substructure.,  8  (11): [PMID:29152047] [10.1021/acsmedchemlett.7b00263]

368. Cvijetić IN, Verbić TŽ, Ernesto de Resende P, Stapleton P, Gibbons S, Juranić IO, Drakulić BJ, Zloh M..  (2018)  Design, synthesis and biological evaluation of novel aryldiketo acids with enhanced antibacterial activity against multidrug resistant bacterial strains.,  143  [PMID:29133041] [10.1016/j.ejmech.2017.10.045]

369. Wu YZ, Zhang HW, Sun ZH, Dai JG, Hu YC, Li R, Lin PC, Xia GY, Wang LY, Qiu BL, Zhang JF, Ge GB, Lin S..  (2018)  Bysspectin A, an unusual octaketide dimer and the precursor derivatives from the endophytic fungus Byssochlamys spectabilis IMM0002 and their biological activities.,  145  [PMID:29353723] [10.1016/j.ejmech.2018.01.030]

370. Fan T, Hu X, Tang S, Liu X, Wang Y, Deng H, You X, Jiang J, Li Y, Song D..  (2018)  Discovery and Development of 8-Substituted Cycloberberine Derivatives as Novel Antibacterial Agents against MRSA.,  9  (5): [PMID:29795764] [10.1021/acsmedchemlett.8b00094]

371. Papadopoulou MV, Bloomer WD, Rosenzweig HS..  (2017)  The antitubercular activity of various nitro(triazole/imidazole)-based compounds.,  25  (21): [PMID:28993106] [10.1016/j.bmc.2017.09.037]

372. Hu YQ, Gao C, Zhang S, Xu L, Xu Z, Feng LS, Wu X, Zhao F..  (2017)  Quinoline hybrids and their antiplasmodial and antimalarial activities.,  139  [PMID:28800458] [10.1016/j.ejmech.2017.07.061]

373. Gerasyuto AI, Arnold MA, Wang J, Chen G, Zhang X, Smith S, Woll MG, Baird J, Zhang N, Almstead NG, Narasimhan J, Peddi S, Dumble M, Sheedy J, Weetall M, Branstrom AA, Prasad JVN, Karp GM..  (2018)  Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-Pyridone Type II DNA Topoisomerase Inhibitors Active against Multidrug Resistant Gram-negative Bacteria.,  61  (10): [PMID:29727185] [10.1021/acs.jmedchem.8b00114]

374. Song L, Zhang HJ, Deng AJ, Li J, Li X, Li ZH, Zhang ZH, Wu LQ, Wang SQ, Qin HL..  (2018)  Syntheses and structure-activity relationships on antibacterial and anti-ulcerative colitis properties of quaternary 13-substituted palmatines and 8-oxo-13-substituted dihydropalmatines.,  26  (9): [PMID:29680749] [10.1016/j.bmc.2018.04.025]

375. Liu Y, Hu X, Wu Y, Zhang W, Chen X, You X, Hu L..  (2018)  Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria.,  150  [PMID:29604581] [10.1016/j.ejmech.2018.03.031]

376. Odagiri T, Inagaki H, Nagamochi M, Kitamura T, Komoriya S, Takahashi H..  (2018)  Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.,  61  (16): [PMID:30063826] [10.1021/acs.jmedchem.8b00644]

377. Rather MA, Lone AM, Teli B, Bhat ZS, Singh P, Maqbool M, Shairgojray BA, Dar MJ, Amin S, Yousuf SK, Bhat BA, Ahmad Z..  (2017)  The synthesis, biological evaluation and structure-activity relationship of 2-phenylaminomethylene-cyclohexane-1,3-diones as specific anti-tuberculosis agents.,  8  (11): [PMID:30108731] [10.1039/C7MD00350A]

378. Bhat ZS, Ul Lah H, Rather MA, Maqbool M, Ara T, Ahmad Z, Yousuf SK..  (2018)  Synthesis and in vitro evaluation of substituted 3-cinnamoyl-4-hydroxy-pyran-2-one (CHP) in pursuit of new potential antituberculosis agents.,  9  (1): [PMID:30108910] [10.1039/C7MD00366H]

379. Gatadi S, Gour J, Shukla M, Kaul G, Das S, Dasgupta A, Malasala S, Borra RS, Madhavi YV, Chopra S, Nanduri S..  (2018)  Synthesis of 1,2,3-triazole linked 4(3H)-Quinazolinones as potent antibacterial agents against multidrug-resistant Staphylococcus aureus.,  157  [PMID:30176536] [10.1016/j.ejmech.2018.08.070]

380. Stierle AA, Stierle DB, Decato D, Priestley ND, Alverson JB, Hoody J, McGrath K, Klepacki D..  (2017)  The Berkeleylactones, Antibiotic Macrolides from Fungal Coculture.,  80  (4): [PMID:28326781] [10.1021/acs.jnatprod.7b00133]

381. Wang R, Yin X, Zhang Y, Yan W..  (2018)  Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids.,  156  [PMID:30025351] [10.1016/j.ejmech.2018.07.025]

382. Fan TY, Wang YX, Tang S, Hu XX, Zen QX, Pang J, Yang YS, You XF, Song DQ..  (2018)  Synthesis and antibacterial evaluation of 13-substituted cycloberberine derivatives as a novel class of anti-MRSA agents.,  157  [PMID:30145374] [10.1016/j.ejmech.2018.08.050]

383. Franck Touret, Magali Gilles, Karine Barral, Antoine Nougairède, Etienne Decroly, Xavier de Lamballerie, Bruno Coutard.  (2020)  In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication,  [10.1101/2020.04.03.023846]

384. Bernhard Ellinger, Denisa Bojkova, Andrea Zaliani, Jindrich Cinatl, Carsten Claussen, Sandra Westhaus, Jeanette Reinshagen, Maria Kuzikov, Markus Wolf, Gerd Geisslinger, Philip Gribbon, Sandra Ciesek.  (2020)  Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection,  [10.21203/rs.3.rs-23951/v1]

385. Shi C, Zhang Y, Wang T, Lu W, Zhang S, Guo B, Chen Q, Luo C, Zhou X, Yang Y..  (2019)  Design, Synthesis, and Biological Evaluation of Novel DNA Gyrase-Inhibiting Spiropyrimidinetriones as Potent Antibiotics for Treatment of Infections Caused by Multidrug-Resistant Gram-Positive Bacteria.,  62  (6): [PMID:30698430] [10.1021/acs.jmedchem.8b01750]

386. Liu H, Long S, Rakesh KP, Zha GF..  (2020)  Structure-activity relationships (SAR) of triazine derivatives: Promising antimicrobial agents.,  185  [PMID:31675510] [10.1016/j.ejmech.2019.111804]

387. Gao F, Xiao J, Huang G..  (2019)  Current scenario of tetrazole hybrids for antibacterial activity.,  184  [PMID:31605865] [10.1016/j.ejmech.2019.111744]

388. Mabhula A, Singh V..  (2019)  Drug-resistance in Mycobacterium tuberculosis: where we stand.,  10  (8): [PMID:31534654] [10.1039/C9MD00057G]

389. Pham TDM, Ziora ZM, Blaskovich MAT..  (2019)  Quinolone antibiotics.,  10  (10): [PMID:31803393] [10.1039/C9MD00120D]

390. Masci D, Hind C, Islam MK, Toscani A, Clifford M, Coluccia A, Conforti I, Touitou M, Memdouh S, Wei X, La Regina G, Silvestri R, Sutton JM, Castagnolo D..  (2019)  Switching on the activity of 1,5-diaryl-pyrrole derivatives against drug-resistant ESKAPE bacteria: Structure-activity relationships and mode of action studies.,  178  [PMID:31202995] [10.1016/j.ejmech.2019.05.087]

391. Li B, Wang K, Zhang R, Li B, Shen Y, Ji Q..  (2019)  Design, synthesis and biological evaluation of novel diazaspiro[4.5]decan-1-one derivatives as potential chitin synthase inhibitors and antifungal agents.,  182  [PMID:31494473] [10.1016/j.ejmech.2019.111669]

392. Karale UB, Krishna VS, Krishna EV, Choudhari AS, Shukla M, Gaikwad VR, Mahizhaveni B, Chopra S, Misra S, Sarkar D, Sriram D, Dusthackeer VNA, Rode HB..  (2019)  Synthesis and biological evaluation of 2,4,5-trisubstituted thiazoles as antituberculosis agents effective against drug-resistant tuberculosis.,  178  [PMID:31195172] [10.1016/j.ejmech.2019.05.082]

393. Hu X, Hu X, Hu X, Li S, Li L, Yu L, Liu H, You X, Wang Z, Li L, Yang B, Jiang B, Wu L..  (2019)  Cytotoxic and Antibacterial Cervinomycins B_1-4 from a Streptomyces Species.,  82  (8): [PMID:31381332] [10.1021/acs.jnatprod.9b00198]

394. Zhang W, Lun S, Liu LL, Xiao S, Duan G, Gunosewoyo H, Yang F, Tang J, Bishai WR, Yu LF..  (2019)  Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.,  62  (7): [PMID:30875203] [10.1021/acs.jmedchem.9b00010]

395. Gatadi S, Gour J, Shukla M, Kaul G, Kaul G, Dasgupta A, Madhavi YV, Chopra S, Nanduri S..  (2019)  Synthesis and evaluation of new quinazolin-4(3H)-one derivatives as potent antibacterial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis.,  175  [PMID:31096152] [10.1016/j.ejmech.2019.04.067]

396. Narang R, Kumar R, Kalra S, Nayak SK, Khatik GL, Kumar GN, Sudhakar K, Singh SK..  (2019)  Recent advancements in mechanistic studies and structure activity relationship of FoF1 ATP synthase inhibitor as antimicrobial agent.,  182  [PMID:31493745] [10.1016/j.ejmech.2019.111644]

397. Makane VB, Krishna VS, Krishna EV, Shukla M, Mahizhaveni B, Misra S, Chopra S, Sriram D, Dusthackeer VNA, Rode HB..  (2019)  Synthesis and evaluation of α-aminoacyl amides as antitubercular agents effective on drug resistant tuberculosis.,  164  [PMID:30654238] [10.1016/j.ejmech.2019.01.002]

398. Jin C, Alenazy R, Wang Y, Mowla R, Qin Y, Tan JQE, Modi ND, Gu X, Polyak SW, Venter H, Ma S..  (2019)  Design, synthesis and evaluation of a series of 5-methoxy-2,3-naphthalimide derivatives as AcrB inhibitors for the reversal of bacterial resistance.,  29  (7): [PMID:30755336] [10.1016/j.bmcl.2019.02.003]

399. Ma Z, Lynch AS..  (2016)  Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections.,  59  (14): [PMID:27336583] [10.1021/acs.jmedchem.6b00485]

400. Hampannavar GA, Karpoormath R, Palkar MB, Shaikh MS, Chandrasekaran B..  (2016)  Dehydrozingerone Inspired Styryl Hydrazine Thiazole Hybrids as Promising Class of Antimycobacterial Agents.,  7  (7): [PMID:27437078] [10.1021/acsmedchemlett.6b00088]

401. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani.  (2020)  Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen,  [10.6019/CHEMBL4495564]

402. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani.  (2020)  Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen,  [10.6019/CHEMBL4495564]

403. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen.  (2020)  Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort,  [10.6019/CHEMBL4495565]

404. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen.  (2020)  Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort,  [10.6019/CHEMBL4495565]

405. Sarink, M; Mykytyn, A; Tielens, A; van Hellemond, J. Naegleria gruberi Pathogen Box compounds screening,  [10.6019/CHEMBL4513101]

406. Johannes Zuegg, Alysha Elliott, Maite Amado, Emma Cowie, Ali Hinton, Geraldine Kaeslin, Angela Kavanagh, Anne Kunert, Gabriell Lowe, Soumya Ramu, Janet Reid, Robin Trauer, Mathilde Desselle, Ruth Neale, Karl Hansford, Mark Blascovich, Matthew Cooper. CO-ADD screening of NIH (USA) - Clinical Collection,  [10.6019/CHEMBL4513141]

407. Johannes Zuegg, Alysha Elliott, Maite Amado, Emma Cowie, Ali Hinton, Geraldine Kaeslin, Angela Kavanagh, Anne Kunert, Gabriell Lowe, Soumya Ramu, Janet Reid, Robin Trauer, Mathilde Desselle, Ruth Neale, Karl Hansford, Mark Blascovich, Matthew Cooper. CO-ADD screening of MMV (CH) - MMV compounds,  [10.6019/CHEMBL4513149]

408. Johannes Zuegg, Alysha Elliott, Maite Amado, Emma Cowie, Ali Hinton, Geraldine Kaeslin, Angela Kavanagh, Anne Kunert, Gabriell Lowe, Soumya Ramu, Janet Reid, Robin Trauer, Mathilde Desselle, Ruth Neale, Karl Hansford, Mark Blascovich, Matthew Cooper. CO-ADD screening of MMV (CH) - Pandemic Response Box,  [10.6019/CHEMBL4513161]

409. Picconi P, Hind CK, Nahar KS, Jamshidi S, Di Maggio L, Saeed N, Evans B, Solomons J, Wand ME, Sutton JM, Rahman KM..  (2020)  New Broad-Spectrum Antibiotics Containing a Pyrrolobenzodiazepine Ring with Activity against Multidrug-Resistant Gram-Negative Bacteria.,  63  (13): [PMID:32515951] [10.1021/acs.jmedchem.0c00328]

410. Gao F, Zhang X, Wang T, Xiao J..  (2019)  Quinolone hybrids and their anti-cancer activities: An overview.,  165  [PMID:30660827] [10.1016/j.ejmech.2019.01.017]

411. Bera S, Mondal D..  (2019)  Insights of synthetic analogues of anti-leprosy agents.,  27  (13): [PMID:31103404] [10.1016/j.bmc.2019.04.032]

412. Chen X, Liu Y, Wang C, Hu X, Wu Y, Zhang Y, Bian C, You X, Hu L..  (2020)  Synthesis and in vitro activity of asymmetric indole-based bisamidine compounds against Gram-positive and Gram-negative pathogens.,  30  (8): [PMID:32070637] [10.1016/j.bmcl.2019.126887]

413. Aguirre-Rentería SA, Carrizales-Castillo JJJ, Del Rayo Camacho Corona M, Hernández-Fernández E, Garza-González E, Rivas-Galindo VM, Arredondo-Espinoza E, Avalos-Alanís FG..  (2020)  Synthesis and in vitro evaluation of antimycobacterial and cytotoxic activity of new α,β-unsaturated amide, oxazoline and oxazole derivatives from l-serine.,  30  (9): [PMID:32151467] [10.1016/j.bmcl.2020.127074]

414. Camp, Jason E., Nyamini, Simbarashe B., Scott, Fraser J..  (2020)  Cyrene(TM) is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens,  11  (1): [PMID:33479610] [10.1039/c9md00341j]

415. Berry, Liam, Domalaon, Ronald, Brizuela, Marc, Zhanel, George G., Schweizer, Frank.  (2019)  Polybasic peptide-levofloxacin conjugates potentiate fluoroquinolones and other classes of antibiotics against multidrug-resistant Gram-negative bacteria,  10  (4): [PMID:31057731] [10.1039/c9md00051h]

416. Fan BZ,Hiasa H,Lv W,Brody S,Yang ZY,Aldrich C,Cushman M,Liang JH.  (2020)  Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides.,  193  [PMID:32200200] [10.1016/j.ejmech.2020.112222]

417. Zhang B.  (2019)  Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids.,  168  [PMID:30826511] [10.1016/j.ejmech.2019.02.055]

418. Ushiyama F,Amada H,Mihara Y,Takeuchi T,Tanaka-Yamamoto N,Mima M,Kamitani M,Wada R,Tamura Y,Endo M,Masuko A,Takata I,Hitaka K,Sugiyama H,Ohtake N.  (2020)  Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.,  28  (22): [PMID:33032189] [10.1016/j.bmc.2020.115776]

419. Malasala S,Ahmad MN,Akunuri R,Shukla M,Kaul G,Dasgupta A,Madhavi YV,Chopra S,Nanduri S.  (2021)  Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis.,  212  [PMID:33190958] [10.1016/j.ejmech.2020.112996]

420. Kirk R,Betson M,Bingham M,Doyle P,Harvey R,Huxley A,Moat J,Pesnot T,Tait M,Hallworth S,Nelson G.  (2020)  Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections.,  30  (20): [PMID:32799032] [10.1016/j.bmcl.2020.127428]

421. Wang Y,Alenazy R,Gu X,Polyak SW,Zhang P,Sykes MJ,Zhang N,Venter H,Ma S.  (2021)  Design and structural optimization of novel 2H-benzo[h]chromene derivatives that target AcrB and reverse bacterial multidrug resistance.,  213  [PMID:33279291] [10.1016/j.ejmech.2020.113049]

422. Zhang W,Liu LL,Lun S,Wang SS,Xiao S,Gunosewoyo H,Yang F,Tang J,Bishai WR,Yu LF.  (2021)  Design and synthesis of mycobacterial pks13 inhibitors: Conformationally rigid tetracyclic molecules.,  213  [PMID:33516983] [10.1016/j.ejmech.2021.113202]

423. Wang W, Zhang YW, Hu SJ, Niu WP, Zhang GN, Zhu M, Wang MH, Zhang F, Li XM, Wang JX..  (2021)  Design, synthesis, and antibacterial evaluation of PFK-158 derivatives as potent agents against drug-resistant bacteria.,  41  [PMID:33766773] [10.1016/j.bmcl.2021.127980]

424. Guo Y, Hou E, Wen T, Yan X, Han M, Bai LP, Fu X, Liu J, Qin S..  (2021)  Development of Membrane-Active Honokiol/Magnolol Amphiphiles as Potent Antibacterial Agents against Methicillin-Resistant Staphylococcus aureus (MRSA).,  64  (17.0): [PMID:34432450] [10.1021/acs.jmedchem.1c01073]

425. Ryan MD, Parkes AL, Corbett D, Dickie AP, Southey M, Andersen OA, Stein DB, Barbeau OR, Sanzone A, Thommes P, Barker J, Cain R, Compper C, Dejob M, Dorali A, Etheridge D, Evans S, Faulkner A, Gadouleau E, Gorman T, Haase D, Holbrow-Wilshaw M, Krulle T, Li X, Lumley C, Mertins B, Napier S, Odedra R, Papadopoulos K, Roumpelakis V, Spear K, Trimby E, Williams J, Zahn M, Keefe AD, Zhang Y, Soutter HT, Centrella PA, Clark MA, Cuozzo JW, Dumelin CE, Deng B, Hunt A, Sigel EA, Troast DM, DeJonge BLM..  (2021)  Discovery of Novel UDP-N-Acetylglucosamine Acyltransferase (LpxA) Inhibitors with Activity against Pseudomonas aeruginosa.,  64  (19.0): [PMID:34569791] [10.1021/acs.jmedchem.1c00888]

426. Lu Y, Vibhute S, Li L, Okumu A, Ratigan SC, Nolan S, Papa JL, Mann CA, English A, Chen A, Seffernick JT, Koci B, Duncan LR, Roth B, Cummings JE, Slayden RA, Lindert S, McElroy CA, Wozniak DJ, Yalowich J, Mitton-Fry MJ..  (2021)  Optimization of TopoIV Potency, ADMET Properties, and hERG Inhibition of 5-Amino-1,3-dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Identification of a Lead with In Vivo Efficacy against MRSA.,  64  (20.0): [PMID:34614347] [10.1021/acs.jmedchem.1c01250]

427. Meenu MT, Kaul G, Shukla M, Radhakrishnan KV, Chopra S..  (2021)  Cudraflavone C from Artocarpus hirsutus as a Promising Inhibitor of Pathogenic, Multidrug-Resistant S. aureus, Persisters, and Biofilms: A New Insight into a Rational Explanation of Traditional Wisdom.,  84  (10.0): [PMID:34546736] [10.1021/acs.jnatprod.1c00578]

428. Pratap Verma D, Ansari MM, Verma NK, Saroj J, Akhtar S, Pant G, Mitra K, Singh BN, Ghosh JK..  (2021)  Tandem Repeat of a Short Human Chemerin-Derived Peptide and Its Nontoxic d-Lysine-Containing Enantiomer Display Broad-Spectrum Antimicrobial and Antitubercular Activities.,  64  (20.0): [PMID:34662112] [10.1021/acs.jmedchem.1c01352]

429. Li H, Fu S, Liu L, Yuan X, Wang Y, Zhang C, Dong H, Satoh T..  (2022)  Synthesis and bioactivities of new N-terminal dipeptide mimetics with aromatic amide moiety: Broad-spectrum antibacterial activity and high antineoplastic activity.,  228  [PMID:34772526] [10.1016/j.ejmech.2021.113977]

430. Xu Y, Li H, Xu S, Liu X, Lin J, Chen H, Yuan Z..  (2022)  Light-Triggered Fluorescence Self-Reporting Nitric Oxide Release from Coumarin Analogues for Accelerating Wound Healing and Synergistic Antimicrobial Applications.,  65  (1.0): [PMID:34918930] [10.1021/acs.jmedchem.1c01591]

431. Kong Q, Pan W, Xu H, Xue Y, Guo B, Meng X, Luo C, Wang T, Zhang S, Yang Y..  (2021)  Design, Synthesis, and Biological Evaluation of Novel Pyrimido[4,5-b]indole Derivatives Against Gram-Negative Multidrug-Resistant Pathogens.,  64  (12.0): [PMID:34080858] [10.1021/acs.jmedchem.1c00621]

432. Xu M, Zhou J, Heng D, Su X, Onakpa MM, Bai Y, Duan JA, Che CT, Bi H, Zhao M..  (2022)  Quinone Derivatives as Promising Anti-Helicobacter pylori Agents from Aerial Parts of Mitracarpus hirtus.,  85  (4.0): [PMID:35412828] [10.1021/acs.jnatprod.1c01163]

433. Hao X, Li S, Wang G, Li J, Peng Z, Zhang Y, Yu L, Gan M..  (2022)  Zelkovamycins F and G, Cyclopeptides with Cα-Methyl-threonine Residues, from an Endophytic Kitasatospora sp.,  85  (7.0): [PMID:35715218] [10.1021/acs.jnatprod.2c00174]

434. Meenu MT, Kaul G, Akhir A, Shukla M, Radhakrishnan KV, Chopra S..  (2022)  Developing the Natural Prenylflavone Artocarpin from Artocarpus hirsutus as a Potential Lead Targeting Pathogenic, Multidrug-Resistant Staphylococcus aureus, Persisters and Biofilms with No Detectable Resistance.,  85  (10.0): [PMID:36222797] [10.1021/acs.jnatprod.2c00621]

435. Lyons A, Kirkham J, Blades K, Orr D, Dauncey E, Smith O, Dick E, Walker R, Matthews T, Bunt A, Finlayson J, Morrison I, Savage VJ, Moyo E, Butler HS, Newman R, Ooi N, Smith A, Charrier C, Ratcliffe AJ, Stokes NR, Best S, Salisbury AM, Craighead M, Cooper IR..  (2022)  Discovery and structure-activity relationships of a novel oxazolidinone class of bacterial type II topoisomerase inhibitors.,  65  [PMID:35231579] [10.1016/j.bmcl.2022.128648]

436. Bhawsar S, Joshi S, Deshpande P, Yeole R, Bhagwat S, Patel M..  (2022)  WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections.,  63  [PMID:35276361] [10.1016/j.bmcl.2022.128665]

437. Kumar Sahoo S, Maddipatla S, Nageswara Rao Gajula S, Naiyaz Ahmad M, Kaul G, Nanduri S, Sonti R, Dasgupta A, Chopra S, Madhavi Yaddanapudi V..  (2022)  Identification of nitrofuranylchalcone tethered benzoxazole-2-amines as potent inhibitors of drug resistant Mycobacterium tuberculosis demonstrating bactericidal efficacy.,  64  [PMID:35487101] [10.1016/j.bmc.2022.116777]

438. Cheng B, Cai Z, Luo Z, Luo S, Luo Z, Cheng Y, Yu Y, Guo J, Ju Y, Gu Q, Xu J, Jiang X, Li G, Zhou H..  (2022)  Structure-Guided Design of Halofuginone Derivatives as ATP-Aided Inhibitors Against Bacterial Prolyl-tRNA Synthetase.,  65  (23.0): [PMID:36394909] [10.1021/acs.jmedchem.2c01496]

439. Qin R, Wang P, Wang B, Fu L, Batt SM, Besra GS, Wu C, Wang Y, Huang H, Lu Y, Li G..  (2022)  Identification of thiophene-benzenesulfonamide derivatives for the treatment of multidrug-resistant tuberculosis.,  231  [PMID:35101648] [10.1016/j.ejmech.2022.114145]

440. Dewangan RP, Verma DP, Verma NK, Gupta A, Pant G, Mitra K, Habib S, Ghosh JK..  (2022)  Spermine-Conjugated Short Proline-Rich Lipopeptides as Broad-Spectrum Intracellular Targeting Antibacterial Agents.,  65  (7.0): [PMID:35297625] [10.1021/acs.jmedchem.1c01809]

441. Mohammed EHM, Lohan S, Tiwari RK, Parang K..  (2022)  Amphiphilic cyclic peptide [W₄KR₅]-Antibiotics combinations as broad-spectrum antimicrobial agents.,  235  [PMID:35339840] [10.1016/j.ejmech.2022.114278]

442. Bass AKA, El-Zoghbi MS, Nageeb EM, Mohamed MFA, Badr M, Abuo-Rahma GEA..  (2021)  Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.,  209  [PMID:33077264] [10.1016/j.ejmech.2020.112904]

443. Du X, Wang M, Hu X, Nie T, Zhu M, Zhang G, You X, Wang Y..  (2022)  Synthesis and biological evaluation of novel N, N'-diarylurea derivatives as potent antibacterial agents against MRSA.,  75  [PMID:36067930] [10.1016/j.bmcl.2022.128975]

444. Brandão P, Marques C, Burke AJ, Pineiro M..  (2021)  The application of isatin-based multicomponent-reactions in the quest for new bioactive and druglike molecules.,  211  [PMID:33421712] [10.1016/j.ejmech.2020.113102]

445. Qin HL, Zhang ZW, Ravindar L, Rakesh KP..  (2020)  Antibacterial activities with the structure-activity relationship of coumarin derivatives.,  207  [PMID:32971428] [10.1016/j.ejmech.2020.112832]

446. Gnanavelu K, K S VK, Eswaran S, Sivashanmugam K..  (2023)  Novel quinoline-piperazine hybrids: the design, synthesis and evaluation of antibacterial and antituberculosis properties.,  14  (1.0): [PMID:36760744] [10.1039/d2md00260d]

447. Mohammed EHM, Lohan S, Ghaffari T, Gupta S, Tiwari RK, Parang K..  (2022)  Membrane-Active Cyclic Amphiphilic Peptides: Broad-Spectrum Antibacterial Activity Alone and in Combination with Antibiotics.,  65  (23.0): [PMID:36442155] [10.1021/acs.jmedchem.2c01469]

448. Verma R, Verma SK, Rakesh KP, Girish YR, Ashrafizadeh M, Sharath Kumar KS, Rangappa KS..  (2021)  Pyrazole-based analogs as potential antibacterial agents against methicillin-resistance staphylococcus aureus (MRSA) and its SAR elucidation.,  212  [PMID:33395624] [10.1016/j.ejmech.2020.113134]

449. Jia Y, Zhao L..  (2021)  The antibacterial activity of fluoroquinolone derivatives: An update (2018-2021).,  224  [PMID:34365130] [10.1016/j.ejmech.2021.113741]

450. Elattar KM, El-Khateeb AY, Hamed SE..  (2022)  Insights into the recent progress in the medicinal chemistry of pyranopyrimidine analogs.,  13  (5.0): [PMID:35694689] [10.1039/d2md00076h]

451. Fan YL, Cheng XW, Wu JB, Liu M, Zhang FZ, Xu Z, Feng LS..  (2018)  Antiplasmodial and antimalarial activities of quinolone derivatives: An overview.,  146  [PMID:29360043] [10.1016/j.ejmech.2018.01.039]

452. Gao C, Fan YL, Zhao F, Ren QC, Wu X, Chang L, Gao F..  (2018)  Quinolone derivatives and their activities against methicillin-resistant Staphylococcus aureus (MRSA).,  157  [PMID:30179746] [10.1016/j.ejmech.2018.08.061]

453. Gao F, Wang P, Yang H, Miao Q, Ma L, Lu G..  (2018)  Recent developments of quinolone-based derivatives and their activities against Escherichia coli.,  157  [PMID:30193220] [10.1016/j.ejmech.2018.08.095]

454. Sharma A, De Rosa M, Singla N, Singh G, Barnwal RP, Pandey A..  (2021)  Tuberculosis: An Overview of the Immunogenic Response, Disease Progression, and Medicinal Chemistry Efforts in the Last Decade toward the Development of Potential Drugs for Extensively Drug-Resistant Tuberculosis Strains.,  64  (8.0): [PMID:33826327] [10.1021/acs.jmedchem.0c01833]

455. Durcik M, Cotman AE, Toplak Ž, Možina Š, Skok Ž, Szili PE, Czikkely M, Maharramov E, Vu TH, Piras MV, Zidar N, Ilaš J, Zega A, Trontelj J, Pardo LA, Hughes D, Huseby D, Berruga-Fernández T, Cao S, Simoff I, Svensson R, Korol SV, Jin Z, Vicente F, Ramos MC, Mundy JEA, Maxwell A, Stevenson CEM, Lawson DM, Glinghammar B, Sjöström E, Bohlin M, Oreskär J, Alvér S, Janssen GV, Sterk GJ, Kikelj D, Pal C, Tomašič T, Peterlin Mašič L..  (2023)  New Dual Inhibitors of Bacterial Topoisomerases with Broad-Spectrum Antibacterial Activity and In Vivo Efficacy against Vancomycin-Intermediate Staphylococcus aureus.,  66  (6): [PMID:36877255] [10.1021/acs.jmedchem.2c01905]

456. Singh SB..  (2016)  Discovery and development of kibdelomycin, a new class of broad-spectrum antibiotics targeting the clinically proven bacterial type II topoisomerase.,  24  (24): [PMID:27143131] [10.1016/j.bmc.2016.04.043]

457. Mishra SK, Tripathi G, Kishore N, Singh RK, Singh A, Tiwari VK..  (2017)  Drug development against tuberculosis: Impact of alkaloids.,  137  [PMID:28628823] [10.1016/j.ejmech.2017.06.005]

458. Sutherland JJ, Yonchev D, Fekete A, Urban L..  (2023)  A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.,  14  (1): [PMID:37468498] [10.1038/s41467-023-40064-9]

459. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, 

460. Unpublished dataset, 

461. WHO Anatomical Therapeutic Chemical Classification, 

462. British National Formulary (72nd edition), 

463. Unpublished dataset, 

464. European Medicines Agency, 

Source

Source(15):

• Scientific Literature
• PubChem BioAssays
• Clinical Candidates
• FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)
• USP Dictionary of USAN and International Drug Names
• DrugMatrix
• TP-search Transporter Database
• AstraZeneca Deposited Data
• MMV Pathogen Box
• Curated Drug Pharmacokinetic Data
• CO-ADD antimicrobial screening data
• WHO Anatomical Therapeutic Chemical Classification
• British National Formulary
• SARS-CoV-2 Screening Data 2020-21
• European Medicines Agency